[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 618
1. Blohmer JU, Reinhardt M, Schmalisch G, Lichtenegger W, Hausschild M, Kümmel S, Fischer T, Ohlinger R, Thomas A: Videodensitometry in the examination of focal breast lesions after injection of an ultrasound contrast agent. Anticancer Res; 2006 Mar-Apr;26(2C):1691-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present investigation aimed at assessing the possibility of distinguishing between malignant and benign breast lesions by measuring the signal intensity in vessels of the suspect lesions over time after administration of the ultrasound contrast agent Levovist.
  • MATERIALS AND METHODS: Levovist was administered intravenously to 21 patients with breast cancer and 12 patients with a benign breast lesion.
  • RESULTS: The differences between the benign and the malignant lesions for the parameters T(max) and T(90%) were statistically significant.
  • The malignant foci showed a significantly more rapid in-flow of the contrast agent (p = 0.006) than the benign lesions.
  • The wash-in wash-out time for Levovist was significantly shorter for the malignant lesions than for the benign lesions (p = 0.02).
  • The specificity and sensitivity made a more precise differentiation between benign and malignant tumors possible.
  • CONCLUSION: The use of a contrast agent in Doppler ultrasound enhances the diagnostic reliability in distinguishing between malignant and benign lesions, justifying the use of a contrast agent with a high specificity (92%) such as Levovist.
  • [MeSH-minor] Contrast Media. Female. Fibroadenoma / blood supply. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617563.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


2. Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL: HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res; 2005 Sep 1;65(17):7782-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries.
  • [MeSH-minor] Animals. Apoptosis / physiology. Cell Cycle / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. DNA, Antisense / genetics. Humans. Hyaluronic Acid / biosynthesis. Isoenzymes. Male. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / enzymology. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140946.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01-CA061038; United States / PHS HHS / / R01 072821-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / Isoenzymes; 9004-61-9 / Hyaluronic Acid; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


3. Milas M, Mazzaglia P, Chia SY, Skugor M, Berber E, Reddy S, Gupta M, Siperstein A: The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery; 2007 Feb;141(2):137-46; discussion 146
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Since 2002, 258 patients had prospective TSHR mRNA measurement by quantitative RT-PCR from peripheral blood before and/or after thyroidectomy.
  • When FNAB specimens indicated follicular neoplasm, a decision algorithm combining TSHR mRNA and abnormal thyroid ultrasound features correctly diagnosed all cancer patients (100% sensitivity) and would have spared operation for benign disease in 38%.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263967.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Thyrotropin
  •  go-up   go-down


Advertisement
4. Mitchell DC, Bryan BA: Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. J Cell Biochem; 2010 Oct 15;111(3):543-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Healthy cells, as well as benign and malignant tumors, depend upon the body's blood supply to bring in oxygen and nutrients and carry away waste products.
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Drug Resistance, Neoplasm. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20626031.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


5. Korzeniewska M, Kołomecki K, Stepień H, Naze M, Stepień T, Kuzdak K: [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors]. Endokrynol Pol; 2005 Jan-Feb;56(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
  • On the other hand the mean VEGF (334.2 pg/ml) concentration in patients with benign adrenocortical adenoma wasn't significant different than in control group (p>0.05) but mean sVEGFR-1 (21.7 pg/ml) and sVEGFR-2 (7106.4 pg/ml) concentrations were significantly lower than in the control (p<0.05).
  • [MeSH-major] Adrenal Cortex Neoplasms / blood. Adrenal Cortex Neoplasms / pathology. Biomarkers, Tumor / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adrenocortical Adenoma / blood. Adrenocortical Adenoma / pathology. Adrenocortical Carcinoma / blood. Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / secondary. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Vascular Endothelial Growth Factor Receptor-1 / blood. Vascular Endothelial Growth Factor Receptor-2 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16335673.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


6. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol; 2008 Nov;3(11):1317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
  • INTRODUCTION AND METHODS: We investigated the diagnostic and prognostic value of soluble mesothelin-related proteins (SMRP) in sera from patients with newly diagnosed malignant pleural mesothelioma (MPM) (n = 100), MPM patients at tumor relapse (n = 29), primary lung cancer (n = 139), and benign asbestosis (n = 75) using Mesomark--enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • RESULTS: SMRP concentrations were significantly higher in MPM compared with benign asbestosis (p < 0.001) or lung cancer (p < 0.001).
  • [MeSH-major] Asbestosis / diagnosis. Biomarkers, Tumor / blood. Lung Neoplasms / diagnosis. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate


7. Lokeshwar VB, Cerwinka WH, Lokeshwar BL: HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res; 2005 Mar 15;65(6):2243-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas HYAL1-S and vector tumors infiltrated skeletal muscle and blood vessels, HYAL1-AS tumors resembled benign neoplasia.
  • [MeSH-minor] Apoptosis / physiology. Cell Cycle / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Extracellular Matrix / metabolism. Humans. Hyaluronic Acid / metabolism. Neoplasm Invasiveness. Neoplasm Transplantation. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / pathology. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781637.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 072821-06A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


8. Guzzo M, Ferrari A, Marcon I, Collini P, Gandola L, Pizzi N, Casanova M, Mattavelli F, Scaramellini G: Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan. Pediatr Blood Cancer; 2006 Nov;47(6):806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The major salivary glands were the main site of tumor occurrence (79% of cases arose in parotid glands); 37 patients had benign tumors (pleomorphic adenoma), 15 had malignant tumors (12 mucoepidermoid carcinoma, 9 low grade).
  • All the patients were treated by surgery; local relapses after parotidectomy were 4% and 25%, in benign and malignant tumors, respectively.
  • When tumor enucleation was performed, recurrences occurred in 50% of benign neoplasms.
  • At the time of the report, all patients with benign tumors were alive, 35(95%) without evidence of disease; only one patient with malignant tumor died of disease.
  • Parotidectomy (total or superficial) is the best choice for achieving good cure rates in both benign and malignant tumors.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Carcinoma, Acinar Cell / surgery. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Neoplasm Recurrence, Local / surgery. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16425245.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Ahmed AS, Dew T, Lawton FG, Papadopoulos AJ, Devaja O, Raju KS, Sherwood RA: Tumour M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study. Eur J Gynaecol Oncol; 2007;28(2):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blood samples were collected before surgery for plasma TU M2-PK assays.
  • RESULTS: 100 patients were recruited; 52 diagnosed with invasive ovarian cancer, 13 with borderline tumours and 35 patients had benign conditions.
  • The mean M2-PK concentration in cancer patients was 52 U/ml vs 31 U/ml in patients with borderline tumours and 22 U/ml in those with benign conditions (p < 0.001); it was significantly raised in association with late stage disease and higher grade (p < 0.05).
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / surgery. Pyruvate Kinase / blood
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. London. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Prospective Studies. ROC Curve. Reproducibility of Results. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17479670.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
  •  go-up   go-down


10. Hakverdi S, Dolapçioğlu K, Güngören A, Yaldiz M, Hakverdi AU: Multiple uterine angioleiomyomas mimicking an ovarian neoplasm: a case report. Eur J Gynaecol Oncol; 2009;30(5):592-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple uterine angioleiomyomas mimicking an ovarian neoplasm: a case report.
  • Angioleiomyoma is a rare benign neoplasm that originates from smooth muscle cells and contains thick-walled blood vessels.
  • Here, we present a case of giant-multiple uterine angioleiomyomas mimicking an ovarian neoplasm.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899426.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Peng SF, Wang SJ, Chen JG, Dai XL, Shi Y, Li YZ, Su ZL, Xue Y, He ZQ, Huang XX, Xu HX: [Detection and significance of transcription factors and cytokines of Th17/Treg cells in peripheral blood in the gastric cancer patients]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection and significance of transcription factors and cytokines of Th17/Treg cells in peripheral blood in the gastric cancer patients].
  • OBJECTIVE: To detect the expression levels of transcription factors and associated cytokines of Th17 and Treg cells in peripheral blood mononuclear cells (PBMC) of patients with gastric cancer, and explore the possible pathological mechanism of these cells involved in the development of gastric cancer.
  • METHODS: The mRNA levels of RORgammat, FoxP3 in PBMC were determined by quantitative real-time PCR (QRT-PCR) from 57 patients with gastric cancer, 31 patients with benign gastric illness and 40 healthy people.
  • The ratio of FoxP3/RORgammat in gastric cancer group was higher than that in the volunteer group and benign gastric illness group (P < 0.05).
  • [MeSH-minor] Adult. Aged. Female. Gastritis / blood. Gastritis / metabolism. Gastritis / pathology. Humans. Interleukin-10 / blood. Interleukin-17 / blood. Interleukin-23 / blood. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. Transforming Growth Factor beta / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450585.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / IL10 protein, human; 0 / Interleukin-17; 0 / Interleukin-23; 0 / Nuclear Receptor Subfamily 1, Group F, Member 3; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10
  •  go-up   go-down


12. Suzuki T, Ueda Y, Shincho M, Mitsui Y, Higuchi Y, Maruyama T, Kondoh N, Nojima M, Yamamoto S, Hirota S, Shima H: [Myolipoma arising from the renal capsule: a case report]. Hinyokika Kiyo; 2008 May;54(5):349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor contained no AML-like blood vessels, and was negative for HMB-45 staining.
  • Myolipoma is a rare benign neoplasm in the soft tissue of retroperitoneum and abdominal cavity.
  • Since it is difficult to distinguish myolipoma from other benign and malignant tumors with fat tissue only by imaging studies, a surgical approach should be considered.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546859.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Gadomska H, Grzechocińska B, Janecki J, Nowicka G, Powolny M, Marianowski L: Serum lipids concentration in women with benign and malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol; 2005 May 1;120(1):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum lipids concentration in women with benign and malignant ovarian tumours.
  • Serum lipid and lipoprotein association with neoplasm is already established.
  • In our study, we have examined concentration of total cholesterol, free cholesterol, HDL cholesterol, HDL3 and HDL free cholesterol fraction, triglycerides, and apolipoproteins: AI, AII and B and aimed to prepare the most likely model of lipid profile in women suffering from ovarian neoplasm.
  • The serum lipid parameters were analysed in 91 operated patients: 64 with ovarian malignant tumour, 27 with benign ovarian cysts and 44 apparently healthy age-matching pair women as a control group.
  • THE RESULTS: concentration of two parameters: apolipoprotein AI and free cholesterol allows for excluding ovarian neoplasm in 95.5%; examination of six parameters: apolipoprotein AI, free cholesterol, HDL-free cholesterol, HDL total cholesterol, apolipoprotein B and HDL3 fraction allows for diagnosing ovarian malignancy with 97% probability.
  • No statistically significant difference between malignant and benign ovarian tumour has been confirmed.
  • [MeSH-major] Lipids / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Apolipoprotein A-I / blood. Apolipoprotein A-II / blood. Apolipoproteins B / blood. Body Mass Index. Cholesterol / blood. Cholesterol, HDL / blood. Female. Humans. Lipoproteins, HDL / blood. Lipoproteins, HDL3. Middle Aged. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15866092.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Apolipoprotein A-II; 0 / Apolipoproteins B; 0 / Cholesterol, HDL; 0 / Lipids; 0 / Lipoproteins, HDL; 0 / Lipoproteins, HDL3; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


14. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW Jr: Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer; 2009 Nov 15;125(10):2288-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While prostate tumor tissues with Gleason scores >or= 7, displayed predominantly nuclear CXCR5 expression patterns, PCa specimens with Gleason scores <or= 6 showed predominantly membrane and cytoplasmic expression patterns that were comparable to benign prostatic hyperplasia (BPH).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - CXCR5 - data and references .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1991 May;5(8):2145-54 [1850705.001]
  • [Cites] Immunity. 2002 Sep;17(3):363-73 [12354388.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):325-43 [8281616.001]
  • [Cites] Semin Cancer Biol. 1996 Jun;7(3):147-54 [8773300.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1666-76 [15467730.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Mol Immunol. 2005 May;42(7):799-809 [15829268.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] J Bone Joint Surg Br. 1998 Nov;80(6):1005-8 [9853493.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Ann Med. 1999 Feb;31(1):34-45 [10219712.001]
  • [Cites] Prostate. 2000 Jan;42(1):18-25 [10579795.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] Eur J Haematol. 2000 May;64(5):323-32 [10863978.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Oral Dis. 2000 Nov;6(6):376-82 [11355270.001]
  • [Cites] J Exp Med. 2002 Jul 1;196(1):65-75 [12093871.001]
  • [Cites] Urol Oncol. 2005 Jul-Aug;23(4):261-7 [16018941.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2613-8 [15972452.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):124-34 [16161154.001]
  • [Cites] Life Sci. 2006 Mar 13;78(16):1784-93 [16263140.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] J Exp Med. 2002 May 6;195(9):1145-54 [11994419.001]
  • [Cites] Science. 2002 Jul 19;297(5580):409-12 [12130787.001]
  • [Cites] Cancer Lett. 2009 Sep 28;283(1):29-35 [19375853.001]
  • [Cites] Eur Respir J. 2002 Nov;20(5):1206-12 [12449175.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1642-6 [12902460.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):613-7 [15033669.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4693-8 [15256432.001]
  • [Cites] FASEB J. 2004 Aug;18(11):1240-2 [15180966.001]
  • [Cites] Nature. 1980 Mar 6;284(5751):67-8 [6243750.001]
  • [Cites] Cell. 1986 Nov 21;47(4):487-98 [3022933.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9576-82 [17018614.001]
  • [Cites] J Int Med Res. 2007 Nov-Dec;35(6):753-61 [18034988.001]
  • [Cites] Cancer Immunol Immunother. 2008 Apr;57(4):541-8 [17786442.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4283-94 [18057003.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(2):197-250 [8435466.001]
  • (PMID = 19610059.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118638; United States / NCRR NIH HHS / RR / G12 RR003034; United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NIMHD NIH HHS / MD / P60 MD000525-03; United States / NIMHD NIH HHS / MD / MD00525; United States / NIMHD NIH HHS / MD / P60 MD000525; United States / NIAID NIH HHS / AI / AI057808; United States / NCI NIH HHS / CA / U54 CA118638-06; United States / NIGMS NIH HHS / GM / S06 GM008248; United States / NIGMS NIH HHS / GM / GM09248; United States / NIAID NIH HHS / AI / R01 AI057808; United States / NIDDK NIH HHS / DK / DK58967; United States / NIAID NIH HHS / AI / AI057808-05; United States / NCI NIH HHS / CA / U54 CA118638-07; United States / NCI NIH HHS / CA / U24 CA086359; United States / NIGMS NIH HHS / GM / GM08248; United States / NCI NIH HHS / CA / U56 CA092078; United States / NIAID NIH HHS / AI / R01 AI057808-05; United States / NCI NIH HHS / CA / CA086359; United States / NCI NIH HHS / CA / CA092078
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / CXCR5 protein, human; 0 / Chemokine CXCL13; 0 / RNA, Messenger; 0 / Receptors, CXCR5; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS137666; NLM/ PMC3600527
  •  go-up   go-down


15. Yang Y, Nie X, Lu J, Lu XY, Wei YY, Wang H, Han ZH, Chen ZH, Zheng J: [Mixed epithelial and stromal tumor of kidney]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):29-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stromal elements essentially consisted of spindle cells, with thick-walled blood vessels and bands of smooth muscle cells as distinctive features of the tumor.
  • CONCLUSIONS: Mixed epithelial and stromal tumor of the kidney is a benign neoplasm with distinct histopathological features.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608646.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


16. Hedayati M, Kołomecki K, Pasieka Z, Korzeniowska M, Kuzdak K: [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors]. Endokrynol Pol; 2005 May-Jun;56(3):252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors].
  • The aim of this study is to evaluate the concentrations of crucial angiogenic cytokine VEGF and its soluble receptors in peripheral blood of patients with benign and malignant thyroid tumors.
  • The study comprised 35 patients with thyroid cancer and 10 patients with follicular neoplasm, both diagnosed by means of ultrasound-guided fine-needle aspiration biopsy.
  • Analysing obtained results, we demonstrated high VEGF concentrations and low soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors.
  • Disequilibrium of the above-mentioned angiogenic factor concentrations is probably essential for the growth and progression of benign and malignant thyroid tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Receptors, Vascular Endothelial Growth Factor / blood. Thyroid Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adult. Aged. Biopsy. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350718.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


17. Teefey SA, Dahiya N, Middleton WD, Gelberman RH, Boyer MI: Ganglia of the hand and wrist: a sonographic analysis. AJR Am J Roentgenol; 2008 Sep;191(3):716-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 60 ganglia, 34 were complex, 91% of which were located within the dorsal or volar wrist; 97% had well-defined margins; 76%, locules; 68%, acoustic enhancement; 47%, a thick wall; 15%, internal reflectors; and 12%, blood flow.
  • A small percentage have blood flow and internal reflectors.
  • Solid-appearing ganglia, although unusual, may mimic a benign neoplasm or synovitis.

  • MedlinePlus Health Information. consumer health - Ultrasound.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716098.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


18. Kołomecki K, Maciaszczyk P, Stepień H, Cywiński J, Cielecka J, Stepień T, Kuzdak K: [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors]. Endokrynol Pol; 2006 Jul-Aug;57(4):320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors].
  • Blood concentration of proteins regulating both pathways of apoptosis may be useful in early diagnosis and staging of thyroid tumors.
  • The aim of study was evaluation of p53 and sFasL blood concentration in patients with benign follicular adenoma and follicular thyroid cancer.
  • MATERIALS AND METHODS: The study population was composed of 28 patients: 14 with thyroid carcinoma and 14 patients with follicular neoplasm (NF).
  • RESULTS: The analysis revealed high sFasL blood concentration in patients with follicular thyroid cancer in comparison with the group with follicular adenoma.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenoma / blood. Biomarkers, Tumor / blood. Fas Ligand Protein / blood. Thyroid Neoplasms / blood. Tumor Suppressor Protein p53 / blood
  • [MeSH-minor] Apoptosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006831.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fas Ligand Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


19. Hernández-Hernández A, Rodríguez MC, López-Revuelta A, Sánchez-Gallego JI, Shnyrov V, Llanillo M, Sánchez-Yagüe J: Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. Blood Cells Mol Dis; 2006 May-Jun;36(3):355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer can be associated with hematological complications related to red blood cell (RBC) function, whose physiological roles have now been expanded since it is now known that RBC are also signalling cells.
  • Blood samples from 21 patients with advanced (stages III-IV) NSCLC (16 squamous cell carcinomas and 5 adenocarcinomas), and from 21 healthy volunteers were used.
  • Additionally, 5 patients with chronic obstructive pulmonary disease (COPD) were used as a control group representative of a benign inflammatory disease.
  • Blood samples from the COPD patients were used to analyze the expression of GPs, band 3 and syaloglycoproteins.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Erythrocyte Membrane / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lung Diseases, Obstructive / metabolism. Lung Diseases, Obstructive / pathology. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574438.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Hori T, Wagata T, Takemoto K, Shigeta T, Takuwa H, Hata K, Uemoto S, Yokoo N: Spontaneous necrosis of solid gallbladder adenocarcinoma accompanied with pancreaticobiliary maljunction. World J Gastroenterol; 2008 Oct 14;14(38):5933-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Doppler US revealed that this elevated lesion had no blood flow.
  • We were agonized in making the qualitative diagnosis of mass-like lesions of the fundus, such as a benign tumor, cancer, or debris.
  • [MeSH-minor] Aged. Cholangiography. Cholecystectomy, Laparoscopic. Cholecystitis, Acute / surgery. Fatal Outcome. Gallstones / surgery. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Necrosis. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gallbladder adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):208-12 [16377119.001]
  • [Cites] Vnitr Lek. 2004 Oct;50(10):781-5 [15633935.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):355-61 [17693282.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1188-93 [17712596.001]
  • [Cites] Postgrad Med J. 2000 Feb;76(892):96-8 [10644387.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):631-5 [10919001.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(1):95-100 [11294297.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):340-8 [11466688.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):447-54 [12734095.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2086-8 [6627217.001]
  • [Cites] Surg Gastroenterol. 1984;3(2):69-73 [6085899.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Eur J Endocrinol. 1994 May;130(5):469-71 [8180674.001]
  • [Cites] Hepatogastroenterology. 1995 Apr;42(2):113-6 [7545638.001]
  • [Cites] Br J Urol. 1995 Oct;76(4):501-3 [7551893.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1224-5 [9373301.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):62-8 [9426519.001]
  • [Cites] Cancer Invest. 1998;16(1):64-5 [9474255.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):423-7 [9690533.001]
  • [Cites] Am Surg. 1998 Aug;64(8):764-7 [9697909.001]
  • [Cites] J Clin Endocrinol Metab. 1953 Aug;13(8):997-1008 [13069604.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2549-55 [16688800.001]
  • (PMID = 18855999.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2751910
  •  go-up   go-down


21. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • GLUT1 staining was intense in cytoplasmic membrane, and was stronger in areas far away from blood vessels and near the necrotic center.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


22. Gupta C, Malani AK, Gupta V, Singh J, Ammar H: Metastatic retroperitoneal epithelioid angiomyolipoma. J Clin Pathol; 2007 Apr;60(4):428-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipoma (AML) is a rare benign neoplasm that usually arises in the kidneys, but may rarely originate in sites such as the retroperitoneum, liver and bone.
  • It is characterised by an intimate admixture of blood vessels, smooth muscle and fat.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 May;36(5):451-6 [10792487.001]
  • [Cites] Pathol Int. 2000 Aug;50(8):649-54 [10972864.001]
  • [Cites] Histopathology. 2002 Mar;40(3):286-90 [11895495.001]
  • [Cites] Saudi Med J. 2002 Sep;23(9):1124-6 [12370727.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2208-16 [9827727.001]
  • [Cites] Am J Clin Pathol. 1989 Dec;92(6):805-8 [2589248.001]
  • [Cites] South Med J. 1997 Jan;90(1):59-62 [9003826.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):180-7 [9500218.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):663-72 [9630173.001]
  • [Cites] Int J Surg Pathol. 2003 Jul;11(3):223-8 [12894358.001]
  • (PMID = 17405979.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2001107
  •  go-up   go-down


23. Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C: Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand; 2009;88(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine whether urine can be used to measure specific ovarian cancer proteomic profiles and whether one peak alone or in combination with other peaks or CA125 has the sensitivity and specificity to discriminate between ovarian cancer pelvic mass and benign pelvic mass.
  • Of the women, 156 had benign gynaecological tumors, 13 had borderline tumors and 40 had malignant epithelial ovarian cancer.
  • RESULTS: Benign and malignant ovarian cancer cases were compared; 21 significantly different peaks (p<0.001) were visualized using Mann-Whitney analysis, ranging in m/z values from 1,500 to 185,000.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Biopsy, Needle. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry. Laparotomy / methods. Middle Aged. Neoplasm Staging. Pelvic Neoplasms / blood. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / urine. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Proteomics. ROC Curve. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023702.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


24. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr, Terstappen LW: Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol; 2005 Jul;27(1):49-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors.
  • EpCAM expression of CTC was compared to tumor cells in paraffin-embedded tissue arrays containing various benign diseases and carcinomas.
  • FCM analysis of CTC from 100 metastatic carcinoma patients with > or =2 CTC/90 microl blood showed EpCAM expression ranging from 9,900 to 246,000 (mean 49,700) antigens per cell.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Epithelial Cells / cytology. Gene Expression Regulation, Neoplastic. Neoplasms / blood
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line, Tumor. Down-Regulation. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Immunohistochemistry. Immunomagnetic Separation. Mice. Neoplasm Metastasis. Neoplastic Cells, Circulating. Paraffin / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942643.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 8002-74-2 / Paraffin
  •  go-up   go-down


25. Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol; 2008 Jul;110(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
  • While EpCAM-positive exosomes were detectable in both patients with benign ovarian disease and ovarian cancer, exosomal microRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease.
  • [MeSH-major] Biomarkers, Tumor / blood. MicroRNAs / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Endocytosis. Female. Gene Expression Profiling. Humans. Lipid Bilayers. Neoplasm Staging. RNA, Neoplasm / blood. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2008 Jul;110(1):1-2 [18589207.001]
  • [ErratumIn] Gynecol Oncol. 2010 Jan;116(1):153
  • (PMID = 18589210.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98166
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipid Bilayers; 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


26. Borghei P, Baradaranfar MH, Borghei SH, Sokhandon F: Transnasal endoscopic resection of juvenile nasopharyngeal angiofibroma without preoperative embolization. Ear Nose Throat J; 2006 Nov;85(11):740-3, 746
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile nasopharyngeal angiofibroma (JNA) is a benign, highly vascular, and locally invasive tumor.
  • The amount of intraoperative blood loss was acceptable.
  • [MeSH-minor] Adolescent. Adult. Balloon Occlusion. Blood Loss, Surgical / prevention & control. Child. Humans. Male. Nasal Cavity. Neoplasm Recurrence, Local / surgery. Preoperative Care. Reoperation. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168151.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Sinha AA, Morgan JL, Wood N, Betre K, Reddy A, Wilson MJ, Ramanani DM: Heterogeneity of cathepsin B and stefin A expression in Gleason pattern 3+3 (score 6) prostate cancer needle biopsies. Anticancer Res; 2007 May-Jun;27(3B):1407-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cathepsin B and stefin A reaction products were found in the cytoplasm of basal and columnar/cuboidal cells of benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and neoplastic cells.
  • [MeSH-minor] Aged. Biopsy, Needle. Cystatin A. Humans. Immunochemistry. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595755.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 1002003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cystatin A; 0 / Cystatins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


28. Yang JG, Li CL, Gong M, Zou LF: [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):683-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 66 patients were proven to have lung cancer by pathology, and 38 patients had benign lung diseases.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / blood. Carcinoembryonic Antigen / blood. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / radionuclide imaging. Female. Humans. Keratin-19. Keratins / blood. Male. Middle Aged. Phosphopyruvate Hydratase / blood. Plasma Cell Granuloma, Pulmonary / blood. Plasma Cell Granuloma, Pulmonary / diagnosis. Plasma Cell Granuloma, Pulmonary / radionuclide imaging. Positron-Emission Tomography. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tuberculosis, Pulmonary / blood. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274375.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Radiopharmaceuticals; 0 / antigen CYFRA21.1; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


29. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW Jr: Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett; 2009 Sep 28;283(1):29-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we present the first evidence that CXCL13, the only ligand for CXCR5, and IL-6 were significantly elevated in PCa patient serum compared to serum from subjects with benign prostatic hyperplasia (BPH), or high-grade prostatic intraepithelial neoplasia (HGPIN) as well as normal healthy donors (NHD).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Urology. 2004 Feb;63(2):316-20 [14972481.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4693-8 [15256432.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1297-301 [15371827.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):918-24 [6681595.001]
  • [Cites] Br J Cancer. 1987 Jan;55(1):61-6 [3814476.001]
  • [Cites] J Orthop Res. 1990 Sep;8(5):764-8 [2388115.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7786-8 [2253221.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(11):637-44 [7688749.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):325-43 [8281616.001]
  • [Cites] J Urol. 1994 May;151(5):1396-9 [7512667.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27 [7529430.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Connect Tissue Res. 1997;36(3):231-40 [9512891.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1743-8 [9676850.001]
  • [Cites] J Bone Joint Surg Br. 1998 Nov;80(6):1005-8 [9853493.001]
  • [Cites] Front Biosci. 1998 Dec 15;3:D1274-9 [9851913.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Prostate. 1999 May;39(2):108-18 [10221566.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24 [10379964.001]
  • [Cites] J Urol. 1999 Aug;162(2):293-306 [10411025.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1666-76 [15467730.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):399-408 [15672864.001]
  • [Cites] N Engl J Med. 2005 May 12;352(19):1977-84 [15888698.001]
  • [Cites] Urol Oncol. 2005 Jul-Aug;23(4):261-7 [16018941.001]
  • [Cites] Horm Metab Res. 2005 Oct;37(10):593-601 [16278781.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):124-34 [16161154.001]
  • [Cites] Life Sci. 2006 Mar 13;78(16):1784-93 [16263140.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):698-700 [17635126.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4283-94 [18057003.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2288-95 [19610059.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] Science. 2000 Sep 1;289(5484):1501-4 [10968779.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):25-33 [11918080.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] J Cell Physiol. 2003 Jan;194(1):71-9 [12447991.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8093-101 [14603250.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]
  • (PMID = 19375853.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / G12 RR003034-27; United States / NCRR NIH HHS / RR / G12 RR003034-23; United States / NCRR NIH HHS / RR / G12 RR003034; United States / NCI NIH HHS / CA / U24 CA086359-10; United States / NIMHD NIH HHS / MD / P60 MD000525-03; United States / NIMHD NIH HHS / MD / MD00525; United States / NIMHD NIH HHS / MD / P60 MD000525; United States / NIAID NIH HHS / AI / AI057808; United States / NCRR NIH HHS / RR / RR003034-23; United States / NIGMS NIH HHS / GM / S06 GM008248; United States / NIGMS NIH HHS / GM / GM09248; United States / NCRR NIH HHS / RR / RR03034; United States / NIGMS NIH HHS / GM / GM008248-22; United States / NIAID NIH HHS / AI / R01 AI057808; United States / NIDDK NIH HHS / DK / DK58967; United States / NCI NIH HHS / CA / U24CA86359.; United States / NCI NIH HHS / CA / U24 CA086359; United States / NIGMS NIH HHS / GM / GM08248; United States / NIGMS NIH HHS / GM / S06 GM008248-22; United States / NCI NIH HHS / CA / U56 CA092078; United States / NCI NIH HHS / CA / CA086359-10; United States / NCI NIH HHS / CA / CA092078
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / CXCR5 protein, human; 0 / Chemokine CXCL13; 0 / Integrins; 0 / Interleukin-6; 0 / Receptors, CXCR5; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS140687; NLM/ PMC3600557
  •  go-up   go-down


30. Kubota Y, Onmura Y, Ohji H, Kunii T, Shibasaki T, Nakada T, Tomita Y: p53 antibodies in the serum of patients with prostate cancer. Int Urol Nephrol; 2008;40(1):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Serum levels of p53-specific antibodies in patients with relapsed, newly diagnosed prostate cancer and in patients with benign prostate hyperplasia were quantified by an enzyme-linked immunoabsorbent assay.
  • RESULT: There was no significant difference (P=0.96) between the serum levels of p53-specific antibodies in patients with newly diagnosed prostate cancer and with benign prostatic hyperplasia.
  • However, the difference between T1c group and benign prostatic hyperplasia group was not significant (P=0.686).
  • The relapsed cancer group tended to have low levels of the antibodies, and, there was no significant difference between the relapsed prostate cancer group and the benign prostatic hyperplasia group (P=0.14).
  • CONCLUSION: The use of titers of p53-specific antibodies to make differential diagnosis between prostate cancer and benign prostatic hyperplasia might have no role, and the antibodies should not be used as a marker of prostate cancer by itself.
  • [MeSH-major] Antibodies, Neoplasm / blood. Biomarkers, Tumor / blood. Prostatic Neoplasms / blood. Tumor Suppressor Protein p53 / immunology
  • [MeSH-minor] Aged. Humans. Male. Prostatic Hyperplasia / blood. Recurrence

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):789-93 [1347085.001]
  • [Cites] Int J Cancer. 1987 Feb 15;39(2):185-9 [3542843.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 [221923.001]
  • [Cites] Gut. 1997 Mar;40(3):356-61 [9135525.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] J Virol. 1979 Aug;31(2):472-83 [225566.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):480-7 [8056443.001]
  • [Cites] J Urol. 1997 Dec;158(6):2278-83 [9366376.001]
  • [Cites] J Urol. 2004 Jan;171(1):182-6 [14665872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3439-42 [1373500.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):682-9 [12548611.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1359-66 [9626451.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4168-74 [1322237.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1894-9 [7933246.001]
  • [Cites] Mod Pathol. 1994 May;7(4):435-9 [8066072.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2534-9 [9874460.001]
  • [Cites] JAMA. 1993 May 26;269(20):2650-8 [8487449.001]
  • (PMID = 17619164.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


31. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A, Tobin D: Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med; 2006 Sep;47(9):1434-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixteen patients with suggestive mammographic findings and 4 patients with benign lesions were included.
  • Safety endpoints were treatment-emergent adverse events (AEs) and changes in a limited physical examination, electrocardiogram (ECG) recordings, blood biochemistry, hematology, coagulation, vital signs, and urine analysis after administration of (99m)Tc-NC100692 and throughout the 24-h follow-up.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / radionuclide imaging. Integrin alphaVbeta3 / metabolism. Neoplasm Proteins / metabolism. Organotechnetium Compounds / pharmacokinetics. Peptides, Cyclic / pharmacokinetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Nucl Med. 2007 Apr;48(4):567
  • (PMID = 16954550.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alphaVbeta3; 0 / Neoplasm Proteins; 0 / Organotechnetium Compounds; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 0 / technetium 99m NC 100692
  •  go-up   go-down


32. Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, Nicosia SV: Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol; 2010 Apr;117(1):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: VEGF, HGF, ES and AS were assayed by ELISA in samples from pilot cohort consisting of healthy women (N=48; pre-menopausal N=23, post-menopausal N=25), women with benign gynecological disease (N=54), patients with primary peritoneal cancer (PP) (N=2) and EOC (N=35).
  • Levels of urinary AS (uAS) from healthy individuals or women with benign gynecological disease averaged 21.4 ng/mL+/-3.7 and 41.5 ng/mL+/-8.8, respectively.
  • [MeSH-minor] Adult. Case-Control Studies. Cohort Studies. Endostatins / blood. Endostatins / urine. Enzyme-Linked Immunosorbent Assay. Epithelial Cells / pathology. Female. Hepatocyte Growth Factor / blood. Hepatocyte Growth Factor / urine. Humans. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / urine. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / urine

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20071014.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 7 P30 CA76292-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endostatins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 67256-21-7 / Hepatocyte Growth Factor; 86090-08-6 / Angiostatins
  •  go-up   go-down


33. McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM: Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res; 2006 Jun 15;12(12):3856-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi.
  • CONCLUSIONS: TRAIL-R1 and TRAIL-R2 expression is higher in malignant melanocytes than in their benign counterparts, suggesting that these receptors might be effective therapeutic targets in melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41 [14506165.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2205-12 [15520016.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8773-7 [15574790.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8767-72 [15574789.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):165-86 [15389801.001]
  • [Cites] FEBS Lett. 2005 Mar 28;579(9):1940-4 [15792800.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3126-35 [15837769.001]
  • [Cites] Pathology. 2004 Dec;36(6):561-5 [15841691.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5188-94 [16033835.001]
  • [Cites] J Invest Dermatol. 2005 Nov;125(5):1010-9 [16297203.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11185-92 [16322269.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Forum (Genova). 2000 Jul-Sep;10(3):243-52 [11007932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):635-40 [11149963.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):4891-8 [11290766.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):966s-973s [11300498.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5337-45 [11313369.001]
  • [Cites] Blood. 2001 Aug 1;98(3):795-804 [11468181.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7339-48 [11585775.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1420-9 [12649208.001]
  • [Cites] Cell Death Differ. 2003 May;10(5):558-69 [12728254.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5390-400 [14500373.001]
  • [Cites] Exp Cell Res. 2005 Mar 10;304(1):244-55 [15707589.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1463-70 [14977850.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):831-40 [14982837.001]
  • [Cites] Lab Invest. 2004 Mar;84(3):320-31 [14767486.001]
  • [Cites] Melanoma Res. 2004 Jun;14(3):207-10 [15179190.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):333-9 [15251125.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Oncogene. 2004 Aug 19;23(37):6261-71 [15208660.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Mayo Clin Proc. 1997 Apr;72(4):367-71 [9121186.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1743-51 [9586887.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2195-200 [9725211.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2833-40 [9743343.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):734-41 [9973225.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2597-605 [10072501.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2747-53 [10364001.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • (PMID = 16778114.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P30 041942; United States / NCI NIH HHS / CA / R21 CA100825-01; United States / NIEHS NIH HHS / ES / K08 ES11571; United States / NIEHS NIH HHS / ES / K08 ES011571; United States / NCI NIH HHS / CA / R21 CA100825; United States / NCI NIH HHS / CA / R0-1 CA115756-01; United States / NCI NIH HHS / CA / R01 CA115756
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human
  • [Other-IDs] NLM/ NIHMS19117; NLM/ PMC1839847
  •  go-up   go-down


34. Witczak K, Szpurek D, Moszyński R, Sroka Ł, Sajdak S: [Clinical assessment of selected vascularization attributes of adnexal masses in preoperative prediction of tumor malignancy]. Ginekol Pol; 2007 May;78(5):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: This study included 521 women diagnosed and treated for adnexal masses (181 malignant and 340 benign) in Obstetrics and Gynecology Hospital of University of Medical Sciences in Poznan between 1994 and 2004.
  • [MeSH-major] Neovascularization, Pathologic / diagnostic imaging. Ovarian Neoplasms / blood supply. Ovarian Neoplasms / diagnostic imaging. Ovary / blood supply
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Diseases / blood. Ovarian Diseases / diagnostic imaging. Poland. Predictive Value of Tests. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867328.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


35. Dapri G, Himpens J, Ntounda R, Alard S, Dereeper E, Cadière GB: Enucleation of a leiomyoma of the mid-esophagus through a right thoracoscopy with the patient in prone position. Surg Endosc; 2010 Jan;24(1):215-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyoma is the most common benign esophageal neoplasm.
  • RESULTS: Total operative time was 85 min and blood loss was less than 20 ml.
  • Benign pathology was confirmed.
  • Gravity displaces blood loss eventually, which allows good visualization, and the surgeon can operate in an ergonomic position.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2007 Dec;39(12):1097-9 [18072062.001]
  • [Cites] J Appl Physiol (1985). 2000 Mar;88(3):1076-83 [10710406.001]
  • [Cites] Anesth Analg. 1995 May;80(5):955-60 [7726438.001]
  • [Cites] Scand Cardiovasc J. 1997;31(6):361-4 [9455786.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):713-6 [15026895.001]
  • [Cites] J Clin Gastroenterol. 2000 Jul;31(1):89-90 [10914787.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):257-62 [7670685.001]
  • [Cites] Surg Today. 1997;27(2):189-92 [9018003.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1122-5 [15797036.001]
  • [Cites] Surg Endosc. 1996 Apr;10(4):457-8 [8661804.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Apr;14(2):87-90 [15287607.001]
  • [Cites] Acta Chir Belg. 1996 Sep-Oct;96(5):223-5 [8950384.001]
  • [Cites] Surg Endosc. 2006 Dec;20(12):1904-8 [16960671.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jul;134(1):176-81 [17599505.001]
  • [Cites] Br J Surg. 1992 Jul;79(7):643 [1643473.001]
  • [Cites] J Surg Oncol. 1986 Nov;33(3):166-9 [3773534.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2008 Feb;18(1):20-6 [18266569.001]
  • [Cites] Surg Endosc. 2004 Jun;18(6):924-30 [15108112.001]
  • [Cites] Int J Surg. 2007 Oct;5(5):328-31 [17638600.001]
  • [Cites] Ann Thorac Surg. 1992 Sep;54(3):576-7 [1510534.001]
  • [Cites] Dis Esophagus. 2009;22(3):279-83 [19021682.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):7-11 [1573620.001]
  • [Cites] Int Surg. 1997 Jan-Mar;82(1):5-6 [9189788.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):78-81 [17505413.001]
  • [Cites] Curr Probl Surg. 1976 Mar;13(3):1-74 [1253619.001]
  • [Cites] Thorax. 1998 Mar;53(3):190-2 [9659354.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):136-46 [14698321.001]
  • [Cites] J Thorac Cardiovasc Surg. 1974 Dec;68(6):953-6 [4420581.001]
  • (PMID = 19517189.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Ma YX, Ye F, Chen HZ, Lü WG, Xie X: [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125]. Zhonghua Yi Xue Za Zhi; 2007 Mar 20;87(11):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
  • OBJECTIVE: To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125.
  • METHODS: Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry.
  • Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20).
  • Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor.
  • RESULTS: In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05).
  • The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05).
  • In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances).
  • In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.
  • [MeSH-minor] Adult. Fas Ligand Protein / biosynthesis. Female. Flow Cytometry. Humans. Middle Aged. Neoplasm Staging


37. Gläsker S, Berlis A, Pagenstecher A, Vougioukas VI, Van Velthoven V: Characterization of hemangioblastomas of spinal nerves. Neurosurgery; 2005 Mar;56(3):503-9; discussion 503-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemangioblastoma is classified as a benign tumor of the central nervous system.
  • [MeSH-minor] Adult. Blood Loss, Surgical. Diagnosis, Differential. Female. Humans. Infratentorial Neoplasms / epidemiology. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / radiography. Infratentorial Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neurilemmoma / diagnosis. Neuroma / diagnosis. Retrospective Studies. Treatment Outcome. von Hippel-Lindau Disease / epidemiology. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / radiography. von Hippel-Lindau Disease / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730575.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


38. Karube K, Nabeshima K, Ishiguro M, Harada M, Iwasaki H: cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol; 2006 Feb;59(2):160-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To identify genes differentially expressed in MPNST compared with benign tumours, such as neurofibromas and schwannomas, by means of cDNA microarray analysis.
  • METHODS: Six MPNST cases and five benign cases (three schwannomas and two neurofibromas) were analysed.
  • Immunohistochemistry confirmed upregulation of survivin in MPNST at the protein level in six of eight cases compared with benign tumours.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Nerve Sheath Neoplasms / metabolism. Peripheral Nervous System Neoplasms / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 1999 Dec;1(8):461-6 [10587640.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):648-57 [1991849.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):1-9 [10699960.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:127-30 [10707794.001]
  • [Cites] Growth Horm IGF Res. 2000 Dec;10(6):349-59 [11161966.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):965-9 [11581297.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):636-43 [1712747.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Growth Regul. 1991 Sep;1(3):125-30 [1726837.001]
  • [Cites] Annu Rev Physiol. 1993;55:131-53 [8466170.001]
  • [Cites] Cell Biol Int. 1993 Mar;17(3):325-9 [7685649.001]
  • [Cites] Pathol Res Pract. 1994 Apr;190(4):412-5 [8078812.001]
  • [Cites] Experientia. 1995 Sep 29;51(9-10):853-62 [7556567.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4522-9 [8813151.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1879-85 [9816144.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):120-4 [15611790.001]
  • [Cites] Trends Mol Med. 2001 Dec;7(12):542-7 [11733216.001]
  • [Cites] Diagn Mol Pathol. 2002 Mar;11(1):33-40 [11854600.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] J Pathol. 2002 Jul;197(3):388-94 [12115886.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Histopathology. 2003 Mar;42(3):280-91 [12605648.001]
  • [Cites] J Neurooncol. 2003 May;62(3):321-8 [12777085.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):706-12 [12866030.001]
  • [Cites] Clin Exp Dermatol. 2003 Sep;28(5):515-20 [12950343.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1019-27 [14559985.001]
  • [Cites] BMC Dev Biol. 2001;1:5 [11305929.001]
  • [Cites] J Pathol. 2003 Nov;201(3):430-8 [14595755.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):529-38 [14767537.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Cell. 1990 Jul 13;62(1):187-92 [1694727.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):617-23 [10698506.001]
  • (PMID = 16443732.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1860323
  •  go-up   go-down


39. Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, von Ruecker A, Bastian PJ: CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate; 2008 Jan 1;68(1):42-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed serum samples from 226 consecutive patients (168 PCA; 42 benign prostatic hyperplasia (BPH); 5 incidental PCA; 11 healthy individuals).
  • [MeSH-major] CpG Islands / physiology. DNA Methylation. DNA, Neoplasm / blood. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Cell Cycle Proteins / genetics. Cyclooxygenase 2 / genetics. Genetic Testing / methods. Glutathione S-Transferase pi / genetics. Glycoproteins / genetics. Humans. Male. Membrane Proteins / genetics. Middle Aged. Prognosis. Serum

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18004747.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Glycoproteins; 0 / Membrane Proteins; 0 / RARRES1 protein, human; 0 / RPRM protein, human; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


40. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ: Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood; 2010 Sep 16;116(11):1919-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Langerhans cells in LCH are clonal, their benign morphology and their lack (to date) of reported recurrent genomic abnormalities have suggested that LCH may not be a neoplasm.


41. Eversole R, Su L, ElMofty S: Benign fibro-osseous lesions of the craniofacial complex. A review. Head Neck Pathol; 2008 Sep;2(3):177-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibro-osseous lesions of the craniofacial complex. A review.
  • Benign fibro-osseous lesions of the craniofacial complex are represented by a variety of disease processes that are characterized by pathologic ossifications and calcifications in association with a hypercellular fibroblastic marrow element.
  • [MeSH-minor] DNA, Neoplasm / analysis. Humans. Mutation

  • MedlinePlus Health Information. consumer health - Paget's Disease of Bone.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet A. 2006 Dec 1;140(23):2646-706 [17103447.001]
  • [Cites] Eur J Endocrinol. 2006 Dec;155(6):839-43 [17132753.001]
  • [Cites] J Bone Miner Res. 2006 Dec;21 Suppl 2:P120-4 [17229000.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Jul;94(1):111-4 [12193904.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1622-3; author reply 1622-3 [12432053.001]
  • [Cites] J Craniofac Surg. 2002 Nov;13(6):765-8 [12457091.001]
  • [Cites] Eur Radiol. 2002 Dec;12 Suppl 3:S109-13 [12522617.001]
  • [Cites] Radiol Med. 2002 Oct;104(4):377-81 [12569322.001]
  • [Cites] Oral Oncol. 2002 Dec;38(8):785-92 [12570058.001]
  • [Cites] Tex Dent J. 2003 Feb;120(2):178, 188-9 [12674967.001]
  • [Cites] Todays FDA. 2002 Dec;14(12):20-1 [12703510.001]
  • [Cites] J Virol Methods. 2003 May;109(2):253-9 [12711070.001]
  • [Cites] J Mass Dent Soc. 2003 Spring;52(1):52-4 [12723214.001]
  • [Cites] Dentomaxillofac Radiol. 2003 May;32(3):141-9 [12917278.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118 Suppl:S50-70 [14569813.001]
  • [Cites] Cleft Palate Craniofac J. 2003 Nov;40(6):632-8 [14577811.001]
  • [Cites] J Bone Miner Res. 2003 Dec;18(12):2095-104 [14672344.001]
  • [Cites] Int Endod J. 2003 Dec;36(12):907-11 [14689960.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):69-74 [14745727.001]
  • [Cites] J Oral Pathol Med. 2004 Apr;33(4):246-8 [15061714.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Apr;62(4):519 [15085526.001]
  • [Cites] Ophthalmology. 2000 Aug;107(8):1464-7 [10919890.001]
  • [Cites] Arch Pathol. 1963 May;75:480-95 [13973557.001]
  • [Cites] Ital J Orthop Traumatol. 1976 Aug;2(2):221-37 [1024109.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1977 May;18(3):360-8 [899860.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1978 Feb;45(2):167-74 [272598.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Mar;65(3):339-42 [3162582.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Aug;66(2):249-60 [3140161.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Jun;67(6):698-705 [2740093.001]
  • [Cites] Gaoxiong Yi Xue Ke Xue Za Zhi. 1989 May;5(5):299-303 [2778863.001]
  • [Cites] J Oral Surg (Chic). 1956 Jan;14(1):3-14 [13278814.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5459-64 [15331575.001]
  • [Cites] Arch Oral Biol. 2005 Feb;50(2):115-22 [15721137.001]
  • [Cites] Pediatr Blood Cancer. 2005 Apr;44(4):390-6 [15602717.001]
  • [Cites] Otol Neurotol. 2005 Mar;26(2):237-40 [15793411.001]
  • [Cites] Bone. 2005 Mar;36(3):542-8 [15777670.001]
  • [Cites] Br Dent J. 2005 Apr 23;198(8):477-8 [15849576.001]
  • [Cites] Clin Genet. 2005 Aug;68(2):190-1 [15996221.001]
  • [Cites] JBR-BTR. 2005 May-Jun;88(3):156-7 [16038240.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):350-6 [16053841.001]
  • [Cites] J Am Dent Assoc. 2005 Jul;136(7):927-31 [16060474.001]
  • [Cites] Clin Sci (Lond). 2005 Sep;109(3):257-63 [16104845.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:97-102 [16131876.001]
  • [Cites] J Bone Miner Res. 2005 Oct;20(10):1845-50 [16160742.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Oct;63(10):1549-54 [16182928.001]
  • [Cites] J Bone Joint Surg Am. 2005 Nov;87(11):2489-94 [16264125.001]
  • [Cites] Skeletal Radiol. 2005 Dec;34(12):793-8 [16096755.001]
  • [Cites] Bone. 2006 Feb;38(2 Suppl 2):S3-7 [16406763.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2107-13 [15126527.001]
  • [Cites] J Oral Sci. 2004 Mar;46(1):61-4 [15141726.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):498-501 [15183415.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):630-2 [15103427.001]
  • [Cites] Braz Dent J. 2004;15(1):75-8 [15322650.001]
  • [Cites] Semin Nephrol. 2004 Sep;24(5):449-55 [15490409.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1967 Oct;24(4):435-48 [5235465.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1968 Mar;25(3):479-84 [5237482.001]
  • [Cites] J Can Dent Assoc (Tor). 1969 Apr;35(4):208-12 [5251764.001]
  • [Cites] J Oral Surg. 1972 Jul;30(7):517-9 [4503603.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1973 Mar;35(3):340-50 [4510606.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1973 Feb;35(2):190-201 [4513065.001]
  • [Cites] J Oral Pathol. 1972;1(5):189-220 [4199101.001]
  • [Cites] Br J Oral Surg. 1974 Mar;11(3):230-5 [4526020.001]
  • [Cites] Arch Otolaryngol. 1974 Sep;100(3):233-6 [4852156.001]
  • [Cites] Int J Oral Surg. 1974;3(6):440-4 [4217321.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1975 Apr;39(4):590-604 [1054467.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1976 Jan;41(1):62-82 [1061039.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 May;19 Suppl 2:577-82 [16789620.001]
  • [Cites] J Craniomaxillofac Surg. 1993 Oct;21(7):294-7 [8263214.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Dec;71(2):170-2 [8281522.001]
  • [Cites] Tumori. 1993 Oct 31;79(5):363-6 [8116084.001]
  • [Cites] Br J Oral Maxillofac Surg. 2006 Aug;44(4):322-4 [16310907.001]
  • [Cites] Ann N Y Acad Sci. 2006 Apr;1068:143-64 [16831914.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):503-14 [16877352.001]
  • [Cites] Calcif Tissue Int. 2006 Jul;79(1):22-6 [16868670.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 May;2(5):270-7 [16932700.001]
  • [Cites] Am J Otolaryngol. 2006 Sep-Oct;27(5):358-61 [16935186.001]
  • [Cites] J Oral Pathol Med. 1995 Jul;24(6):285-7 [7562667.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1155-65 [8630892.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1853-9 [8625058.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Mar;81(3):333-42 [8653468.001]
  • [Cites] Semin Diagn Pathol. 1996 May;13(2):104-12 [8734416.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Feb;25(1):54-6 [8833301.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Nov;82(5):577-84 [8936524.001]
  • [Cites] Minerva Stomatol. 1996 Jul-Aug;45(7-8):349-54 [8984329.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Dec;82(6):704-12 [8974145.001]
  • [Cites] Dentomaxillofac Radiol. 1996 Jun;25(3):125-9 [9084260.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Apr;55(4):410-4; 414-5 [9120707.001]
  • [Cites] Curr Opin Rheumatol. 1997 Jul;9(4):347-54 [9229182.001]
  • [Cites] Head Neck. 1997 Sep;19(6):513-23 [9278760.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Sep;84(3):301-9 [9377196.001]
  • [Cites] J Bone Miner Res. 1997 Nov;12(11):1952-3 [9383700.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1963 May 8;38:175-89 [13996066.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Sep;70(3):301-7 [2216357.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Sep;70(3):308-12 [2216358.001]
  • [Cites] Bone Miner. 1990 Nov;11(2):209-16 [2268748.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan-Feb;12(1):25-30 [1899514.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Aug;70(2):241-2 [2290659.001]
  • [Cites] Dentomaxillofac Radiol. 1990 Aug;19(3):137-8 [2088788.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jun;156(6):1199-203 [2028867.001]
  • [Cites] Br J Oral Maxillofac Surg. 1991 Jun;29(3):194-7 [1873290.001]
  • [Cites] J Otolaryngol. 1992 Apr;21(2):112-4 [1583704.001]
  • [Cites] Bone Miner. 1992 Nov;19(2):159-74 [1345324.001]
  • [Cites] Ohio Dent J. 1992 Spring-Summer;66(1):65-8 [1436943.001]
  • [Cites] Acta Otolaryngol Suppl. 1991;488:1-40 [1843064.001]
  • [Cites] Radiol Clin North Am. 1993 Jan;31(1):121-34 [8419969.001]
  • [Cites] Ann Rheum Dis. 1992 Dec;51(12):1335-7 [1485818.001]
  • [Cites] J Oral Maxillofac Surg. 1993 Aug;51(8):828-35 [8336219.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1993 Aug;76(2):200-4 [8361732.001]
  • [Cites] Dentomaxillofac Radiol. 1993 May;22(2):93-6 [8375561.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(4):391-8 [16429324.001]
  • [Cites] J Clin Rheumatol. 2006 Apr;12(2):57-60 [16601537.001]
  • [Cites] J Bone Miner Metab. 2006;24(3):186-90 [16622730.001]
  • [Cites] Joint Bone Spine. 2006 May;73(3):243-8 [16574459.001]
  • [Cites] Calcif Tissue Int. 2006 May;78(5):271-7 [16691492.001]
  • [Cites] J Clin Pathol. 1982 Jul;35(7):771-9 [7096600.001]
  • [Cites] J Bone Miner Res. 1994 Jan;9(1):11-6 [8154304.001]
  • [Cites] Clin Nephrol. 1994 Mar;41(3):173-9 [8187362.001]
  • [Cites] Hum Mol Genet. 1994 Feb;3(2):359-61 [7911698.001]
  • [Cites] Quintessence Int. 2007 Mar;38(3):221-7 [17333999.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):389-96 [17334331.001]
  • [Cites] Monatsschr Ohrenheilkd Laryngorhinol. 1949 Jan;83(1):1-10 [18116635.001]
  • [Cites] Med Arh. 2000;54(2):115-8 [10934843.001]
  • [Cites] J Bone Miner Res. 2000 Dec;15(12):2330-44 [11127198.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):67-72 [11272890.001]
  • [Cites] Am J Med Genet. 2001 Mar 1;99(2):132-6 [11241472.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Apr;91(4):438-44 [11312460.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):126-43 [11345237.001]
  • [Cites] Br J Plast Surg. 2001 Dec;54(8):708-11 [11728115.001]
  • [Cites] J Bone Miner Res. 2002 Jan;17(1):26-9 [11771666.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):296-304 [11925539.001]
  • [Cites] Oral Dis. 2002 Mar;8(2):106-10 [11991305.001]
  • [Cites] J Dent Assoc S Afr. 1984 Sep;39(9):641 [6596779.001]
  • [Cites] Plast Reconstr Surg. 1999 Mar;103(3):949-54 [10077086.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Nov;84(5):540-9 [9394387.001]
  • [Cites] Aust Dent J. 1997 Dec;42(6):404-8 [9470284.001]
  • [Cites] Eur J Endocrinol. 1998 May;138(5):557-61 [9625369.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1061-5 [9661069.001]
  • [Cites] Eur Radiol. 1998;8(7):1145-7 [9724428.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Sep;86(3):376-81 [9768431.001]
  • [Cites] Dentomaxillofac Radiol. 1998 Sep;27(5):275-8 [9879216.001]
  • [Cites] J Rheumatol. 1999 Jan;26(1):150-5 [9918257.001]
  • [Cites] Acta Neurol Belg. 1998 Dec;98(4):352-5 [9922824.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Jan;87(1):107-14 [9927089.001]
  • [Cites] Clin Radiol. 1992 May;45(5):316-8 [1516340.001]
  • [Cites] Am J Ophthalmol. 1999 May;127(5):619-21 [10334366.001]
  • [Cites] Am J Hum Genet. 1999 Jul;65(1):158-66 [10364528.001]
  • [Cites] Arch Ital Otol Rinol Laringol. 1953;64(Suppl. 16):1-103 [14350911.001]
  • [Cites] J Oral Surg (Chic). 1957 Apr;15(2):138-42 [13417011.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1958 Jan;11(1):55-68 [13541953.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1418-26 [10667418.001]
  • [Cites] J Clin Invest. 2000 Mar;105(5):607-14 [10712432.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1449-54 [10770180.001]
  • [Cites] J Oral Surg. 1980 Jan;38(1):65-70 [6927901.001]
  • [Cites] Histopathology. 1980 Jan;4(1):63-74 [7353818.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Feb;49(2):117-21 [6928281.001]
  • [Cites] Br J Oral Surg. 1980 Dec;18(3):221-9 [6934818.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Oct;50(4):372-81 [6935588.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1978 Dec;46(6):765-71 [282541.001]
  • [Cites] Acta Otolaryngol Suppl. 1979;360:61-3 [287355.001]
  • [Cites] J Oral Surg. 1979 Oct;37(10):725-31 [289735.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Jun;53(6):647-50 [6954448.001]
  • [Cites] Skeletal Radiol. 1982;9(2):126-8 [7163823.001]
  • [Cites] Dentomaxillofac Radiol. 1983;12(1):51-6 [6574075.001]
  • [Cites] Am J Ophthalmol. 1983 Nov;96(5):650-3 [6638132.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1984 Feb;57(2):195-9 [6583626.001]
  • [Cites] Ear Nose Throat J. 1984 Aug;63(8):383-92 [6468316.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1984 Oct;58(4):456-60 [6593677.001]
  • [Cites] Ophthalmology. 1985 Jan;92(1):150-9 [3974992.001]
  • [Cites] Cancer. 1968 Oct;22(4):861-78 [5212309.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Apr;43(4):249-62 [3856641.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Mar;59(3):269-74 [3856818.001]
  • [Cites] J Gen Virol. 1985 Oct;66 ( Pt 10):2103-10 [2995550.001]
  • [Cites] Nephron. 1985;41(3):223-9 [4058622.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Nov;60(5):505-11 [3864113.001]
  • [Cites] Ear Nose Throat J. 1985 Oct;64(10):466-72 [4064974.001]
  • [Cites] J Gen Virol. 1986 May;67 ( Pt 5):907-13 [3701300.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1986 Sep;62(3):340-4 [3462639.001]
  • [Cites] Arch Ophthalmol. 1986 Sep;104(9):1347-51 [3753286.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(6):561-8 [3118565.001]
  • [Cites] J Bone Joint Surg Br. 1988 Mar;70(2):255-60 [3346299.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Sep;78(3):391-6 [7970604.001]
  • [Cites] J Oral Pathol Med. 1994 Oct;23(9):385-8 [7823298.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Nov;78(5):611-20 [7838469.001]
  • [Cites] Yonsei Med J. 1989;30(2):133-43 [2800563.001]
  • [Cites] Clin Orthop Relat Res. 1989 Nov;(248):265-77 [2530018.001]
  • [Cites] Head Neck. 1989 Nov-Dec;11(6):538-44 [2584009.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Dec;68(6):740-7 [2594322.001]
  • [Cites] Br Dent J. 1990 Feb 10;168(3):112-5 [2306394.001]
  • [Cites] J Oral Pathol Med. 1990 Feb;19(2):65-70 [2341974.001]
  • [Cites] J Craniomaxillofac Surg. 1990 Apr;18(3):125-9 [2345185.001]
  • [Cites] J Craniomaxillofac Surg. 1990 May;18(4):169-72 [2193039.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Jul;70(1):81-5 [2371053.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1993 Sep;76(3):351-5 [8378050.001]
  • [Cites] Laryngoscope. 1993 Dec;103(12):1385-90 [8246661.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1993 Nov;76(5):601-7 [8247501.001]
  • (PMID = 20614314.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2807558
  • [Keywords] NOTNLM ; Benign fibroosseous lesions / Cementoma / Cementoosseous dysplasia / Fibrous dysplasia / Ossifying fibroma / Osteitis deformans
  •  go-up   go-down


42. Economidou F, Tzortzaki EG, Schiza S, Antoniou KM, Neofytou E, Zervou M, Lambiri I, Siafakas NM: Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncol Rep; 2007 Dec;18(6):1507-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions.
  • Distinguishing malignant from benign pleural effusions using routine cytology is a common diagnostic problem.
  • Pleural fluid and peripheral blood from 48 patients (36 male and 12 female, median age 71 years) were analyzed.
  • The control group consisted of 22 patients with benign pleural effusions.
  • Only 14 malignancy-associated pleural effusions were cytology-positive for malignant cells (54%), whereas all benign pleural effusions were negative.
  • One out of 22 (4.5%) patients with benign pleural effusion showed LOH in marker D3S134.
  • In conclusion, genetic alterations at the level of microsatellite DNA, were detected only in very few cases of malignant pleural effusions, and in one case of benign pleural effusion.
  • [MeSH-major] DNA / genetics. DNA, Neoplasm / genetics. Microsatellite Repeats. Pleural Effusion / physiopathology. Pleural Neoplasms / physiopathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chromosome Mapping. Chromosomes, Human. Female. Genomic Instability. Humans. L-Lactate Dehydrogenase / analysis. Male. Middle Aged. Neoplasm Proteins / analysis. Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982637.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Proteins; 9007-49-2 / DNA; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


43. Suga Y, Miyajima K, Oikawa T, Maeda J, Usuda J, Kajiwara N, Ohira T, Uchida O, Tsuboi M, Hirano T, Kato H, Ikeda N: Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer. Oncol Rep; 2008 Nov;20(5):1137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer.
  • We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR.
  • Evaluation of p16 and ESR1 promoter methylation in blood using real-time PCR appears to be very useful for lung cancer diagnosis and there is some possibility that these methylated genes might come to represent useful biomarkers for the early detection of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. DNA Methylation. Estrogen Receptor alpha / genetics. Genes, p16. Lung Neoplasms / blood
  • [MeSH-minor] Age Factors. Aged. Carcinoembryonic Antigen / blood. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Female. Hematologic Tests / methods. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Smoking / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949413.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
  •  go-up   go-down


44. Lin H, Qiu SY, Sun SH: [Clinical value of CYFRA 21-1, HER-2/neu and NSE in differential diagnosis of pleural effusion]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Aug;26(8):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To explore the clinical value of CYFRA 21-1, HER-2/neu and NSE as tumor markers for differential diagnosis of malignant and benign pleural effusion.
  • METHODS: Radioimmunoassay and ELISA were used to detect the serum and effusion levels of CYFRA 21-1, HER-2/neu and NSE in 62 patients with malignat pleural effusion and 48 patients with benign pleural effusion.
  • RESULTS: The levels of CYFRA 21-1, HER-2/neu and NSE in serum and pleural effusion in malignant groups were significant higher than those in benign group (P < 0.01).The levels of CYFRA 21-1, HER-2/neu and NSE in pleural effusion were obviously higher than those in serum (P < 0.01 or 0.05).
  • CONCLUSION: The detection of CYFRA 21-1, HER-2/neu and NSE in pleural effusion has certain clinical significance in differential diagnosis of malignant and benign effusions.
  • [MeSH-major] Antigens, Neoplasm. Diagnostic Techniques and Procedures. Keratin-19. Phosphopyruvate Hydratase. Pleural Effusion / diagnosis. Receptor, ErbB-2
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Male. Middle Aged. ROC Curve. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20619104.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


45. Zhang JJ, Ouyang T, Wan WH, Deng GR: [Detection of free tumor-related DNA in the serum of breast cancer patients]. Zhonghua Zhong Liu Za Zhi; 2007 Aug;29(8):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant methylation of E-cadherin and APC genes was detected in tumor tissues, adjacent normal tissues and peripheral blood serum by methylation-specific PCR (MSP).
  • 10 cases with benign breast diseases were selected as control group.
  • [MeSH-major] Breast Neoplasms / genetics. Cadherins / genetics. DNA Methylation. DNA, Neoplasm / blood. Genes, APC. Genes, Tumor Suppressor

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210882.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / DNA, Neoplasm
  •  go-up   go-down


46. Timmerman D, Van Calster B, Jurkovic D, Valentin L, Testa AC, Bernard JP, Van Holsbeke C, Van Huffel S, Vergote I, Bourne T: Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol; 2007 Sep 20;25(27):4194-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
  • PURPOSE: To test the value of serum CA-125 measurements alone or as part of a multimodal strategy to distinguish between malignant and benign ovarian tumors before surgery based on a large prospective multicenter study (International Ovarian Tumor Analysis).
  • PATIENTS AND METHODS: Patients with at least one persistent ovarian mass preoperatively underwent transvaginal ultrasonography using gray scale imaging to assess tumor morphology and color Doppler imaging to obtain indices of blood flow.
  • RESULTS: Data from 809 patients recruited from nine centers were included in the analysis; 567 patients (70%) had benign tumors and 242 (30%) had malignant tumors-of these 152 were primary invasive (62.8%), 52 were borderline malignant (21.5%), and 38 were metastatic (15.7%).
  • CONCLUSION: Adding information on CA-125 to clinical information and ultrasound information does not improve discrimination of mathematical models between benign and malignant adnexal masses.
  • [MeSH-major] Adnexal Diseases / blood. Adnexal Diseases / diagnosis. Antigens, Neoplasm / blood. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 20;26(3):512; author reply 513 [18202431.001]
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4159-61 [17698803.001]
  • (PMID = 17698805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CA-125 Antigen
  •  go-up   go-down


47. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K: Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol; 2008 Mar;24(3):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
  • AIMS: The aims of the present study were to determine the serum concentrations of insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-3 (IGFBP-3) and leptin and insulin resistance in benign and malignant epithelial ovarian tumors, and to discuss the use of these markers in benign-malignant tumor differentiation.
  • Insulin resistance index by homeostasis model assessment (HOMA score) and fasting blood glucose (FBG), serum IGF-I, IGFBP-3, leptin and CA-125 concentrations were determined in all patients preoperatively.
  • RESULTS: According to postoperative histopathology results, the patients were divided into malignant (n = 23), benign (n = 24) and control (n = 31) groups.
  • Serum concentrations of CA-125 were elevated in the malignant group compared with the benign ovarian tumor and control groups (p < 0.05).
  • In contrast, serum IGF-I concentrations were significantly decreased in patients with malignant and benign ovarian tumors compared with controls (p < 0.05).
  • Serum IGFBP-3 concentrations were also found to be lower in women with malignant ovarian tumors than in women with benign tumors (p < 0.05).
  • Serum leptin did not differ among patients with malignant-benign tumors and controls (p > 0.05).
  • However, the present data suggest that low concentrations of IGF-I and IGFBP-3 could be a reliable marker to differentiate benign from malignant ovarian tumors.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor I / analysis. Leptin / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. Postmenopause / blood
  • [MeSH-minor] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Female. Homeostasis. Humans. Insulin Resistance. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335323.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Leptin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


48. Simmons C, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DE: Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer. Anticancer Res; 2009 Jul;29(7):2707-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: In MBC patients with prolonged BP use, there appears to be a state of hyperparathyroidism similar to that seen with BP use in benign bone disease.
  • [MeSH-major] Breast Neoplasms / metabolism. Calcium / metabolism. Diphosphonates / therapeutic use. Neoplasm Metastasis / drug therapy
  • [MeSH-minor] Aged. Case-Control Studies. Female. Humans. Middle Aged. Vitamin D / blood


49. Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC, Wen JM: Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol; 2010 Jul;63(7):599-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Glypican 3 (GPC3) is a heparan sulphate proteoglycan that shows elevated levels in the serum of patients with hepatocellular carcinoma (HCC), but not in healthy blood donors or patients with benign liver disease.
  • It can be used to distinguish HCC from other benign hepatic conditions and metastatic tumours in the liver.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Liver Diseases / diagnosis. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501450.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Neoplasm Proteins
  •  go-up   go-down


50. Ghaemmaghami F, Fakour F, Karimi Zarchi M, Behtash N, Modares Gilani M, Mousavi A, Shariat M: Clinical assessment, gross examination, frozen section of ovarian masses: do patients benefit? Arch Gynecol Obstet; 2008 Sep;278(3):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The overall risk of malignancy in ovarian neoplasm is 13% in premenopausal women and 45% in postmenopausal women.
  • Differentiating benign and malignant disease with frozen section is possible during operation; however, information on patients' history, physical examination, paraclinical criteria (tumour markers, imaging) and gross examination of tumour can also be helpful in planing the surgery.
  • [MeSH-minor] Biopsy. CA-125 Antigen / blood. Diagnosis, Differential. Female. Frozen Sections. Histocytochemistry. Humans. Physical Examination. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed / standards

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259768.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


51. Eccles SA, Box C, Court W: Cell migration/invasion assays and their application in cancer drug discovery. Biotechnol Annu Rev; 2005;11:391-421
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive capacity is the single most important trait that distinguishes benign from malignant lesions.
  • Tumour cells, during intravasation and extravasation of blood and lymphatic channels and when establishing colonies at secondary sites, must move through tissue boundaries that normal adult cells (other than, for example activated leukocytes) do not cross.
  • Similar mechanisms are also utilised by activated endothelial cells during the generation of new blood vessels that enable the sustained growth and dissemination of tumours.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Movement / drug effects. Neoplasm Invasiveness / prevention & control. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216785.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 73
  •  go-up   go-down


52. Gaggioli C, Sahai E: Melanoma invasion - current knowledge and future directions. Pigment Cell Res; 2007 Jun;20(3):161-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The acquisition of invasive behaviour is the key transition in the progression of benign melanocyte hyperplasia to life threatening melanoma.
  • It is hoped that these models will give us a better understanding of how the genes implicated in melanoma progression affect the motility of melanoma cells and their interactions with the ECM, stromal cells and blood vessels.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516924.001).
  • [ISSN] 0893-5785
  • [Journal-full-title] Pigment cell research
  • [ISO-abbreviation] Pigment Cell Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Number-of-references] 120
  •  go-up   go-down


53. Nanashima A, Takeshita H, Tobinaga S, Araki M, Sumida Y, Kunizaki M, Tanaka K, Abo T, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies. Hepatogastroenterology; 2010 Jul-Aug;57(101):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: The subjects were 75 patients who underwent surgical resections including 27 patients with liver carcinomas, 15 with extra-hepatic biliary carcinomas, 14 pancreatic carcinomas and 19 benign diseases.
  • RESULTS: 1CTP level tended to be higher in the malignant diseases than in benign diseases but this difference was not significant (p = 0.065).
  • Compared to benign adenoma, 1CTP level in the malignant diseases was significantly higher (p = 0.049).
  • 1CTP level tended to be higher in patients with cholangitis compared to those with no inflammation or benign tumors (p = 0.065).
  • [MeSH-major] Biliary Tract Neoplasms / pathology. Biomarkers / blood. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / blood. Liver Neoplasms / pathology. Pancreatic Neoplasms / pathology. Peptides / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangitis / blood. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033212.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


54. Casal JI, Barderas R: Identification of cancer autoantigens in serum: toward diagnostic/prognostic testing? Mol Diagn Ther; 2010 Jun 01;14(3):149-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second, thorough validation of the candidate biomarkers has to be carried out to include not just one particular cancer type but different cancers and other benign, inflammatory pathologies, which may give rise to cross-reactions and loss of the specificity and sensitivity of the predictive assay.
  • [MeSH-major] Autoantigens / blood. Molecular Diagnostic Techniques / methods. Neoplasms / blood. Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Antigens, Neoplasm / immunology. Humans. Precision Medicine. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2001 Jul;1(7):890-8 [11503213.001]
  • [Cites] J Exp Med. 1977 Mar 1;145(3):784-9 [233917.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5088-93 [20194765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 [221923.001]
  • [Cites] Science. 2004 Jul 2;305(5680):86-90 [15232106.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5504-10 [15289361.001]
  • [Cites] Genomics. 2000 Apr 1;65(1):1-8 [10777659.001]
  • [Cites] Proteomics. 2003 Nov;3(11):2200-7 [14595819.001]
  • [Cites] Mol Cell Proteomics. 2008 Mar;7(3):600-11 [18077443.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:3 [12747764.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Nov 15;172(10):1308-14 [16109979.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3461-7 [17409457.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):889-92 [18245491.001]
  • [Cites] Nat Methods. 2008 Jun;5(6):535-8 [18469824.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Cancer Lett. 2009 Aug 18;281(1):8-23 [19091462.001]
  • [Cites] Immunol Rev. 2008 Apr;222:328-40 [18364012.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17494-9 [17954908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):103-11 [10328771.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5060-6 [18794547.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):237-42 [16678056.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5120-6 [14613989.001]
  • [Cites] Curr Opin Drug Discov Devel. 2006 May;9(3):380-5 [16729735.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):859-68 [20200435.001]
  • [Cites] Mol Cell Proteomics. 2009 Oct;8(10):2382-95 [19638618.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2298-305 [12114434.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1490-9 [18311903.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4041-7 [12124339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):261-7 [15113102.001]
  • (PMID = 20560676.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantigens
  • [Number-of-references] 35
  •  go-up   go-down


55. Koutsimpelas D, Stripf T, Heinrich UR, Mann WJ, Brieger J: Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol; 2007 Dec;28(8):1094-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Vestibular schwannoma is a benign, slow-growing neoplasm that accounts for 6% of all intracranial tumors.
  • [MeSH-minor] Adult. Aged. Antigens, CD31 / biosynthesis. Antigens, CD31 / genetics. Capillaries / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / pathology. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Regional Blood Flow / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721409.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


56. Kyle CC, Wingo MS, Carey RI, Leveillee RJ, Bird VG: Diagnostic yield of renal biopsy immediately prior to laparoscopic radiofrequency ablation: a multicenter study. J Endourol; 2008 Oct;22(10):2291-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean blood loss was 28 ml (0-400 ml).
  • Final pathology revealed renal cell carcinoma in 95, oncocytic neoplasm in 26, and angiomyolipoma in 9.8 patients were considered to have nondiagnostic biopsies.
  • In this group, final pathology revealed benign cysts in 3, inconclusive specimens in 3, fibrosis in 1, and normal tissue in 1.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937593.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


57. Hauptmann K, Melcher I, Schaser KD: [Differential diagnosis of intramedullary osteosarcomas]. Pathologe; 2008 Nov;29 Suppl 2:240-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to their strong similarity to benign bone tumors they are frequently misdiagnosed as such.
  • [MeSH-minor] Biopsy. Bone and Bones / diagnostic imaging. Bone and Bones / pathology. Diagnosis, Differential. Humans. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Prognosis. Radiography

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 May;31(5):615-8 [10836302.001]
  • [Cites] Skeletal Radiol. 2005 May;34(5):290-4 [15570421.001]
  • [Cites] J Bone Joint Surg Br. 1992 Nov;74(6):883-6 [1447251.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2095-106 [9179055.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):59-63 [14752796.001]
  • [Cites] Am J Clin Pathol. 2006 Apr;125(4):555-81 [16627266.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3068-75 [12784343.001]
  • [Cites] Skeletal Radiol. 2000 Nov;29(11):656-9 [11201036.001]
  • [Cites] Clin Orthop Relat Res. 1996 Jan;(322):198-206 [8542697.001]
  • [Cites] J Bone Joint Surg Am. 1979 Mar;61(2):207-15 [284009.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1627-37 [17351949.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):338-45 [8422626.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1418-28 [2306687.001]
  • (PMID = 18843492.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


58. Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P, Halon A, Staszek U, Szelachowska J, Pudelko M, Bebenek M, Harlozinska-Szmyrka A, Kornafel J: Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res; 2010 Sep;16(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to determine whether VEGF serum levels (VEGF-A, VEGF-C and VEGF-D) in 377 patients with malignant and benign breast tumors differ and whether there is association between vascular growth factors, clinicopathologic features and prognosis.
  • Associations between angiogenic cytokines and number of blood cells may be due to release of VEGF from platelets and leucocytes.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor D / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / mortality. Neovascularization, Pathologic / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 1;94(11):2855-61 [12115372.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4370-9 [15806151.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):512-7 [16750560.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12):1794-7; discussion 1797-8 [17465468.001]
  • [Cites] Indian J Med Res. 2007 Jun;125(6):747-51 [17704550.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4695-704 [16034044.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):467-83 [15982726.001]
  • [Cites] J Cell Mol Med. 2007 Jan-Feb;11(1):120-8 [17367506.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Scand J Clin Lab Invest. 2002;62(5):343-50 [12387579.001]
  • [Cites] Tumour Biol. 2006;27(6):302-8 [17028465.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):928-33 [15383417.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1217-22 [12973845.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):978-85 [17912242.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):553-61 [15668703.001]
  • [Cites] Angiogenesis. 2003;6(4):283-7 [15166496.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3121-8 [9738584.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):135-43 [15692755.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Sep;24(5):426-30 [10542924.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):159-64 [11437102.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3491-4 [11705867.001]
  • (PMID = 19821158.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


59. Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S, Tiemann M, Dörffel W, Parwaresch R: Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res; 2006 Aug 15;12(16):4804-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demethylation of CT45-negative HeLa cells and stimulated peripheral blood lymphocytes induced CT45 expression.
  • As benign lymphoid lesions did not express CT45, the use of Ki-A10 antibody will facilitate the discrimination of Hodgkin's lymphoma from reactive lymphadenopathies.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Hodgkin Disease / immunology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914565.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / CT45A1 protein, human
  •  go-up   go-down


60. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Breast Feeding / statistics & numerical data. Female. Humans. Obesity / complications. Progesterone / blood. Tobacco Use Disorder / complications. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


61. Orsenigo E, Di Palo S, Vignali A, Staudacher C: Laparoscopic excision of duodenal schwannoma. Surg Endosc; 2007 Aug;21(8):1454-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Benign duodenal tumours are rare and less common than malignant tumours.
  • Schwannoma is an ectodermal neoplasm arising from the nerve sheath that envelops axons.
  • Operating time was 300 min and blood loss 200 ml.
  • Histological findings showed a benign schwannoma.
  • CONCLUSIONS: The minimally invasive technique may be a valid alternative to open surgery in the treatment of benign duodenal tumors.

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2003 Jul;33(7):364-6 [12949065.001]
  • [Cites] Minerva Chir. 1998 May;53(5):419-26 [9780634.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):62-7 [8554153.001]
  • [Cites] Chirurg. 1997 Feb;68(2):159-67 [9156983.001]
  • [Cites] Chir Ital. 1979 Dec;31(6):1150-61 [554761.001]
  • [Cites] Arq Gastroenterol. 1996 Oct-Dec;33(4):221-4 [9302337.001]
  • [Cites] Chir Ital. 2004 May-Jun;56(3):443-8 [15287645.001]
  • (PMID = 17177083.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


63. Li X, Qiao Z, Long X, Wei J, Cheng Y: Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br J Oral Maxillofac Surg; 2005 Dec;43(6):513-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum concentrations of AMDL DR-70 were estimated by enzyme linked immuno-sorbent assay in 52 patients with carcinoma of the tongue and compared with 40 controls and 42 patients with benign lesions in the tongue.
  • Thirty-nine patients with carcinoma of the tongue had results above 6 mg/L (75%), compared with 3/40 (7%) in healthy controls and 4/42 (10%) in those with benign tumours.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / diagnosis. Fibrin Fibrinogen Degradation Products / analysis. Fibrinogen / analysis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Fibroma / blood. Follow-Up Studies. Hemangioma / blood. Humans. Male. Middle Aged. Neoplasm Staging. Neurofibroma / blood. Prognosis. Reagent Kits, Diagnostic. Sensitivity and Specificity. Survival Rate

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188352.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibrin Fibrinogen Degradation Products; 0 / Reagent Kits, Diagnostic; 9001-32-5 / Fibrinogen
  •  go-up   go-down


64. Sun ZJ, Zhang L, Zhang WF, Liu B, Li ZB, Zhao YF: A possible hypoxia-induced endothelial proliferation in the pathogenesis of epithelioid hemangioma. Med Hypotheses; 2006;67(5):1133-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid hemangioma is an uncommon benign vascular lesion with distinct clinicopathological characteristics.
  • There is considerable controversy whether epithelioid hemangioma is a reactive lesion or a true neoplasm.
  • [MeSH-minor] Arteriovenous Malformations / complications. Blood Vessels / pathology. Cell Division. Humans

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806726.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


65. Harman SM, Gucciardo F, Heward CB, Granstrom P, Barclay-White B, Rogers LW, Ibarra JA Jr: Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy. Cancer Epidemiol Biomarkers Prev; 2005 Oct;14(10):2310-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS AND METHODS: Seventy-one core-needle breast biopsies were classified as malignant, suspicious, or benign by two independent pathologists blinded to AMAS results.
  • RESULTS: Biopsies were read as 42 (59%) benign, 12 (17%) suspicious, and 17 (24%) malignant.
  • CONCLUSIONS: The AMAS test discriminates suspicious and malignant from benign lesions, but sensitivity is insufficient to identify patients to be spared biopsy and false-positive rates are too high for population screening.
  • [MeSH-major] Biomarkers, Tumor / isolation & purification. Breast Neoplasms / pathology. Neoplasm Proteins
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Anti-Idiotypic / blood. Biopsy, Needle. False Positive Reactions. Female. Humans. Middle Aged. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214910.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 63626-45-9 / malignin
  •  go-up   go-down


66. Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut; 2010 Dec;59(12):1687-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Serum GP73 and alpha-fetoprotein (AFP) were compared in a total of 4217 human subjects in this multicentre study, including 1690 healthy adults, 337 hepatitis B virus (HBV) carriers, 512 patients with cirrhosis, 789 patients with HCC, 61 patients with other malignant liver lesions, 206 patients with benign liver lesions and 622 patients with 14 different kinds of non-liver cancers.
  • Fourteen types of non-liver cancers were analysed; all the benign and other malignant liver lesions had moderate elevations of GP73, albeit at a much lower level than in HCC.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Membrane Proteins / blood
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Hepatectomy. Hepatitis B / diagnosis. Humans. Liver Cirrhosis / diagnosis. Male. Middle Aged. Neoplasm Proteins / blood. Sensitivity and Specificity. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876776.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GOLM1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


67. Ichimura T, Kondo S, Okamura K, Tanaka E, Hirano S: Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm: report of a case. Hepatogastroenterology; 2010 Jan-Feb;57(97):8-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm: report of a case.
  • For patients with benign or low malignant diseases of the pancreas, several organ-preserving surgical techniques of pancreatectomy have been presented for localized lesions.
  • We herein report a patient with widespread intraductal papillary mucinous neoplasm treated successfully with total parenchymal pancreatectomy.
  • A 73-year-old man was diagnosed as main duct intraductal papillary mucinous neoplasm.
  • The postoperative course was uneventful and his blood glucose level had been controlled carefully with insulin formulation.

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422863.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


68. Stettner R, Bogusiewicz M, Rechberger T: [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications]. Ginekol Pol; 2009 Jan;80(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The research conducted in recent years has shown that metalloproteinases and their inhibitors contribute substantially to the ovarian cancer progression, participating both in in situ tumours growth, and the spreading of neoplasm via peritoneal fluid.
  • The assessment of serum concentration of some metalloproteinases and their inhibitors appeared to be useful in differential diagnosis between malignant, borderline and benign ovarian tumours.
  • Moreover, the pre-operational assessment of concentration of TIMP-1 in blood serum allows to select the cases of an ovarian cancer with an aggressive phenotype and unfavourable prognosis.
  • [MeSH-major] Biomarkers, Tumor / blood. Collagenases / blood. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinases / blood
  • [MeSH-minor] Female. Humans. Matrix Metalloproteinase 1 / blood. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Prognosis. Tissue Inhibitor of Metalloproteinase-1 / blood. Tissue Inhibitor of Metalloproteinase-2 / blood. Tissue Inhibitor of Metalloproteinase-3 / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323060.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Tissue Inhibitor of Metalloproteinases; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / Collagenases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Number-of-references] 75
  •  go-up   go-down


69. Chang YJ, Mittal V, Remine S, Manyam H, Sabir M, Richardson T, Young S: Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg; 2006 May;72(5):419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 168 patients who underwent parathyroid excision, 14 (8.3%) had hyperplasia of the parathyroid, 121 (72%) had benign adenoma, 25 (14.8%) had other benign lesions, and 8 (4.7%) patients had primary carcinoma of the parathyroid confirmed by pathology.
  • Our mean serum calcium level was 11.57 mg/dL, which was lower than the mean level (12 mg/dL) for benign hyperparathyroidism.
  • On the other hand, 17 patients with benign histology had tumors greater than 3 cm, and an additional 18 had palpable masses on physical examination.
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / surgery. Aged, 80 and over. Calcium / blood. Female. Humans. Hyperparathyroidism / etiology. Male. Middle Aged. Mitosis. Neoplasm Invasiveness. Parathyroidectomy

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719197.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  •  go-up   go-down


70. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M: RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia; 2009 Sep;11(9):956-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RHAMM (CD168) gene, earlier identified by our group as an immunogenic antigen in acute and chronic leukemia, also showed highly significant overexpression in CaP metastases compared with localized disease and benign prostatic hyperplasia.
  • At the protein level, RHAMM was highest in metastatic tissue samples and significantly higher in neoplastic localized disease compared with benign tissue.
  • [MeSH-major] Antigens, CD44 / metabolism. Antigens, Neoplasm / metabolism. Extracellular Matrix Proteins / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1038-45 [10741732.001]
  • [Cites] Blood. 2005 Aug 1;106(3):938-45 [15827130.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):837-43 [11549576.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • [Cites] BJU Int. 2005 Nov;96(7):990-4 [16225514.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Oct;17(7):572-8 [16238145.001]
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8262-9 [16278482.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):237-42 [16678056.001]
  • [Cites] Urology. 2006 May;67(5):1016-21 [16698361.001]
  • [Cites] J Cell Sci. 2006 Oct 1;119(Pt 19):4059-70 [16968750.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4109-17 [16931630.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):163-72 [17218638.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):310-20 [16864594.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):246-53 [17401464.001]
  • [Cites] Curr Opin Urol. 2007 May;17(3):182-7 [17414516.001]
  • [Cites] Curr Opin Urol. 2007 May;17(3):188-93 [17414517.001]
  • [Cites] Drugs. 2007;67(6):859-69 [17428104.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):290 [17431954.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii36-7 [17491038.001]
  • [Cites] Genomics. 2007 Jun;89(6):666-72 [17459658.001]
  • [Cites] Int Rev Immunol. 2007 May-Aug;26(3-4):223-47 [17558745.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1218-27 [17694548.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jan;134(1):51-7 [17593391.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1357-65 [17978170.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):282-90 [18174258.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4031-3 [18519659.001]
  • [Cites] J Biol Chem. 2008 Jul 4;283(27):18678-84 [18434300.001]
  • [Cites] Neoplasia. 2008 Sep;10(9):977-86 [18714399.001]
  • [Cites] Gut. 2008 Oct;57(10):1413-9 [18436576.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7475-83 [18794135.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):229-33 [18586384.001]
  • [Cites] Clin Genitourin Cancer. 2008 Sep;6(2):134-7 [18824440.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5198-203 [18824702.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7161-6 [19010831.001]
  • [Cites] Int J Oncol. 2009 Mar;34(3):629-39 [19212667.001]
  • [Cites] Annu Rev Immunol. 2009;27:83-117 [19007331.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):312-9 [11859202.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Exp Hematol. 2002 Sep;30(9):1029-35 [12225794.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5517-22 [12359762.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Jun;3(3):219-36 [12769690.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):834-43 [15173267.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] J Neurooncol. 1995 Dec;26(3):221-9 [8750188.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):567-76 [9533523.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] FASEB J. 2005 Feb;19(2):243-5 [15548588.001]
  • [Cites] Oncology. 2005;68(1):2-9 [15741753.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1424-32 [15941951.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • (PMID = 19724689.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Extracellular Matrix Proteins; 0 / hyaluronan-mediated motility receptor
  • [Other-IDs] NLM/ PMC2735808
  •  go-up   go-down


71. Sugiyama T, Nakagawa T, Narita M, Nakamura S, Inui M, Tagawa T: Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies. Oral Dis; 2006 May;12(3):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These cells had infiltrated local blood vessels, salivary glands and muscles.
  • CONCLUSIONS: Because the histopathologic features of OC are similar to those of benign oncocytoma, the diagnosis of OC must be confirmed by a combination of clinical and ultrastructural characteristics.
  • [MeSH-minor] Aged, 80 and over. Cheek / pathology. Humans. Immunohistochemistry. Keratins / analysis. Male. Microscopy, Electron, Transmission. Mitochondria / pathology. Mouth Mucosa / pathology. Mucin-1 / analysis. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700744.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


72. Osaka A, Hasegawa H, Yamada Y, Yanagihara K, Hayashi T, Mine M, Aoyama M, Sawada T, Kamihira S: A novel role of serum cytochrome c as a tumor marker in patients with operable cancer. J Cancer Res Clin Oncol; 2009 Mar;135(3):371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Serum cyto-c levels and lactate dehydrogenase (LD) activity were measured in a total of 257 cases (232 malignant and 25 benign).
  • RESULTS: The serum cyto-c level was significantly higher in patients with malignant tumors than patients with benign tumors (20.6 vs. 15.5 ng/mL; P = 0.017, Mann-Whitney U test).
  • [MeSH-major] Cytochromes c / blood. Neoplasms / blood. Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Disease Progression. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Predictive Value of Tests. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 2004 Apr;342(1-2):127-36 [15026273.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):3-15 [7856735.001]
  • [Cites] Arch Dis Child. 2006 Jun;91(6):469-72 [16443616.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):289-96 [12609567.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):605-17 [15234242.001]
  • [Cites] Int J Lab Hematol. 2009 Jun;31(3):307-14 [18279425.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Pediatr Infect Dis J. 2005 May;24(5):467-70 [15876954.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):167-73 [15800951.001]
  • [Cites] Appl Biochem Biotechnol. 2001 Feb;90(2):97-105 [11297391.001]
  • [Cites] Pancreas. 2000 Mar;20(2):117-22 [10707925.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jun;57(6):759-75 [18188561.001]
  • (PMID = 18825408.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 9007-43-6 / Cytochromes c
  •  go-up   go-down


73. Lee JH, Gong H, Khadem S, Lu Y, Gao X, Li S, Zhang J, Xie W: Androgen deprivation by activating the liver X receptor. Endocrinology; 2008 Aug;149(8):3778-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The androgens-androgen receptor signaling plays an important role in normal prostate development, as well as in prostatic diseases, such as benign hyperplasia and prostate cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Biotechnol. 1999 Dec;10(6):557-63 [10600692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):728-33 [8570624.001]
  • [Cites] Genes Dev. 2000 Nov 15;14(22):2819-30 [11090130.001]
  • [Cites] Genes Dev. 2000 Nov 15;14(22):2831-8 [11090131.001]
  • [Cites] Pathol Res Pract. 1996 Jul;192(7):752-60 [8880876.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):670-97 [8969973.001]
  • [Cites] Chem Biol Interact. 1998 Feb 20;109(1-3):267-78 [9566751.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21856-66 [9705324.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4092-101 [9751487.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7686-9 [15520170.001]
  • [Cites] Clin Sci (Lond). 2005 Jan;108(1):1-11 [15384949.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17813-8 [15601766.001]
  • [Cites] Mol Endocrinol. 2005 Jan;19(1):184-97 [15388788.001]
  • [Cites] Hepatology. 2005 Jan;41(1):168-76 [15619241.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):171-202 [15561802.001]
  • [Cites] Biol Reprod. 2005 Nov;73(5):951-8 [16014817.001]
  • [Cites] J Lipid Res. 2005 Dec;46(12):2657-66 [16150827.001]
  • [Cites] Nat Rev Immunol. 2006 Jan;6(1):44-55 [16493426.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):607-14 [16511593.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):358-65 [16778563.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):379-85 [16778565.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):778-87 [11159850.001]
  • [Cites] Mutat Res. 2001 Oct 1;482(1-2):27-40 [11535246.001]
  • [Cites] Steroids. 2001 Sep;66(9):673-81 [11546555.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6482-6 [16818617.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1902-12 [16823488.001]
  • [Cites] Urol Int. 2006;77(2):135-8 [16888418.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10513-6 [17079473.001]
  • [Cites] Drug Metab Dispos. 2007 Jan;35(1):121-7 [17050650.001]
  • [Cites] Prostate. 2007 Mar 1;67(4):405-9 [17187396.001]
  • [Cites] Hepatology. 2007 Feb;45(2):422-32 [17256725.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1843-9 [17194744.001]
  • [Cites] Mol Endocrinol. 2007 May;21(5):1014-27 [17341595.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1534-43 [17369526.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1781-90 [17536009.001]
  • [Cites] J Med Chem. 2002 May 9;45(10):1963-6 [11985463.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):280-9 [11594786.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38378-87 [11504730.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7558-68 [11604492.001]
  • [Cites] Drug Metab Dispos. 2002 May;30(5):582-5 [11950791.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):165-71 [11988089.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):389-96 [12044015.001]
  • [Cites] Int J Urol. 2002 Jun;9(6):359-61 [12110102.001]
  • [Cites] Endocr Rev. 2002 Oct;23(5):703-32 [12372849.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1243-8 [12411951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2226-30 [12589022.001]
  • [Cites] Mol Endocrinol. 2003 Jun;17(6):985-93 [12690094.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36091-8 [12847102.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44593-9 [12923182.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):89-101 [14619959.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):54-69 [14689582.001]
  • [Cites] Mol Pharmacol. 2004 Feb;65(2):292-300 [14742670.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):765-71 [14744796.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):276-308 [15082523.001]
  • [Cites] Trends Endocrinol Metab. 2004 May-Jun;15(4):158-65 [15109614.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Cell. 2004 Oct 15;119(2):299-309 [15479645.001]
  • [Cites] Prostate. 1987;11(3):229-42 [3684783.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:159-76 [10836131.001]
  • (PMID = 18450964.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES014626; United States / NIEHS NIH HHS / ES / ES014626
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Benzoates; 0 / Benzylamines; 0 / DNA-Binding Proteins; 0 / GW 3965; 0 / Hydroxycholesterols; 0 / Orphan Nuclear Receptors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / liver X receptor; 17711-16-9 / 22-hydroxycholesterol; 3XMK78S47O / Testosterone; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.2 / alcohol sulfotransferase
  • [Other-IDs] NLM/ PMC2488233
  •  go-up   go-down


74. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B: Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst; 2008 Oct 1;100(19):1401-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FISH test was also used to examine AURKA gene copy number in exfoliated cells in voided urine samples from 23 patients with bladder cancer and 7 healthy control subjects (training set), generating a model for bladder cancer detection that was subsequently validated in an independent set of voided urine samples from 100 bladder cancer patients and 148 control subjects (92 healthy individuals and 56 patients with benign urologic disorders).

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Nov;144(5):1288-92 [2231915.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):262-4 [8661133.001]
  • [Cites] Genome Res. 1996 Mar;6(3):187-94 [8963895.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):551-60 [9053853.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3052-65 [9606188.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8703-8 [9671742.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Lab Invest. 2005 Apr;85(4):532-49 [15778693.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5005-15 [16049526.001]
  • [Cites] Nat Cell Biol. 2005 Oct;7(10):937-46 [16184168.001]
  • [Cites] Cancer Lett. 2005 Dec 8;230(1):6-19 [16253756.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):144-6 [10835626.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5406-12 [11103942.001]
  • [Cites] J Urol. 2001 Jan;165(1):42-6; discussion 46 [11125360.001]
  • [Cites] Genome Res. 2001 Jun;11(6):1034-42 [11381030.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46219-24 [11551964.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9 [12208897.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):403-12 [12881723.001]
  • [Cites] BMC Med Res Methodol. 2002;2:4 [11914137.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):55-62 [14702041.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2250-63 [14968109.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4800-9 [15256449.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6066-73 [2822239.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):528-48 [2470666.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):1133-7 [16469639.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):844-52 [16740038.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2726-35 [16763212.001]
  • [ErratumIn] J Natl Cancer Inst. 2008 Dec 3;100(23):1740
  • (PMID = 18812553.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA85078; United States / NCI NIH HHS / CA / R01 CA89716; United States / NCI NIH HHS / CA / R01CA066723; United States / NCI NIH HHS / CA / P50CA91846; United States / NCI NIH HHS / CA / R01 CA151489
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2720731
  •  go-up   go-down


75. Hussein K, Ketterling RP, Hulshizer RL, Kuffel DG, Wiktor AE, Hanson CA, Tefferi A, Van Dyke DL: Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol; 2008 Apr;80(4):318-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis.
  • Peripheral blood (PB) is sometimes used in place of bone marrow (BM) for cytogenetic studies during the evaluation of hematologic malignancies.
  • A total of 242 PB cytogenetic studies from adult patients were performed: clinical diagnosis was a myeloid neoplasm in 169 patients (70%), lymphoid or plasma cell neoplasm in 50 (21%), and a benign/reactive cytopenia or leukocytosis in 23 (9%).
  • [MeSH-major] Hematologic Neoplasms / blood. Hematologic Neoplasms / pathology. Metaphase

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088399.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


76. Orawiec B, Grałek M, Stefańczyk L, Niwald A: Applicability of ultrasound in ocular tumors in children and adolescents. Klin Oczna; 2005;107(7-9):437-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Evaluation of the applicability of ultrasound in children diagnosed for neoplasm of the eye.
  • Evaluation of Doppler ultrasound in visualizing blood vessels within the lesion in eye ball, eye socket and eye lids.
  • Establishing the value of the obtained data concerning the image of vessels and blood flow for the diagnosis, monitoring the course of disease and results of treatment.
  • MATERIAL AND METHODS: The study comprised 80 patients diagnosed and treated for neoplasm of the eye.
  • The presence of vessels in tumor mass and blood flow in tumors were useful for differentiation between malignant and benign tumors.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416991.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


77. Camargo RY, Tomimori EK: [Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma]. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):783-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conversely, nodules presenting benign ultrasonographic characteristics such as hyperechogenicity and a mixed sponge-like aspect, and a concordant cytology, have a negative predictive value of 96.6%.
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Calcinosis / ultrasonography. Humans. Neoplasm Staging / methods. Predictive Value of Tests. Thyroglobulin / blood. Thyroid Nodule / pathology. Thyroid Nodule / ultrasonography. Ultrasonography, Doppler, Color. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891242.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  • [Number-of-references] 50
  •  go-up   go-down


78. Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC: ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res; 2008 Aug 1;14(15):4814-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASPM mRNA was overexpressed in 162 HCC (66%) but not in benign liver tumors.
  • [MeSH-minor] Aged. Blood Vessels / metabolism. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Tumor Suppressor Protein p53 / metabolism

  • Genetics Home Reference. consumer health - ASPM gene.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676753.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASPM protein, human; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


79. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol; 2005 Feb;96(2):516-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the clinical relevance of serum secretory leukocyte protease inhibitor (SLPI) levels in distinguishing patients with ovarian cancers from those with benign ovarian cysts, we determined concentrations with reference to the FIGO stage and other clinical characteristics.
  • METHODS: Preoperative serum SLPI levels were measured in women with invasive epithelial ovarian cancer (n = 55), benign ovarian cysts (n = 25), or normal controls (n = 38) using an enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The serum SLPI concentration was significantly elevated in the ovarian cancer patients (median 67 ng/ml, interquartile range 26-124 ng/ml) as compared to the benign cyst patients (37 and 25-66 ng/ml) or healthy women (32 and 25-43 ng/ml).
  • Using an SLPI cutoff of 50 ng/ml and a CA125 cutoff of 30 units/ml, with both markers elevated the sensitivity was 95%, the specificity was 100%, the positive predictive value was 100%, and the negative predictive value was 89% between the malignant and benign cyst patients.
  • CONCLUSION: Serum SLPI levels could be useful for differentiating benign ovarian cysts from malignancies and to improve the specificity of diagnosis.
  • [MeSH-major] Ovarian Neoplasms / blood. Proteins / metabolism
  • [MeSH-minor] CA-125 Antigen / blood. Case-Control Studies. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / diagnosis. Proteinase Inhibitory Proteins, Secretory. Secretory Leukocyte Peptidase Inhibitor. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661245.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / Proteins; 0 / SLPI protein, human; 0 / Secretory Leukocyte Peptidase Inhibitor
  •  go-up   go-down


80. Picquet J, Blin V, Dussaussoy C, Jousset Y, Papon X, Enon B: Surgical reconstruction of the superior vena cava system: indications and results. Surgery; 2009 Jan;145(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Obstruction of the superior vena cava (SVC) secondary to malignant or benign diseases is rarely treated by surgical reconstruction.
  • The underlying disease was primary bronchopulmonary malignant neoplasm in 50%, mediastinal malignant neoplasm in 21%, and symptomatic benign disease in 29%.
  • Mortality was 0% for patients with benign disease.
  • Our experience suggests that the need for SVC reconstruction should not, however, be considered as a contraindication for resection of a bronchopulmonary or mediastinal neoplasm in an otherwise potentially curable patient, provided it can be achieved in a single block with clear margins.
  • Replacement of the SVC can also be performed with low mortality and morbidity for effective treatment of SVCC secondary to benign disease that fails to respond to medical therapy.
  • [MeSH-major] Blood Vessel Prosthesis Implantation. Saphenous Vein / transplantation. Superior Vena Cava Syndrome / surgery

  • Hazardous Substances Data Bank. TEFLON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081480.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


81. Cserni G, Bori R, Sejben I: Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors. Virchows Arch; 2009 Feb;454(2):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors.
  • Granular cell tumor is generally benign, but rare malignant cases have been documented.
  • Venous invasion was incidentally identified with the orcein elastic stain in an otherwise benign granular cell tumor (propositus case).
  • Four further benign granular cell tumors were also analyzed; venous invasion was discovered in three.
  • [MeSH-major] Blood Vessels / pathology. Elastic Tissue / pathology. Granular Cell Tumor / pathology. Staining and Labeling / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1867-72 [17665249.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):291-8 [15791574.001]
  • [Cites] Histopathology. 2006 Nov;49(5):487-92 [17064294.001]
  • [Cites] Minerva Stomatol. 2006 Jul-Aug;55(7-8):423-30 [17041542.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1465-9 [16253028.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2313-7 [8941000.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):560-5 [18300797.001]
  • [Cites] J Pathol. 1976 Jan;118(1):9-16 [1255302.001]
  • [Cites] Histopathology. 2006 Aug;49(2):107-20 [16879388.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):769-72 [15220375.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):779-94 [9669341.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):208-11 [8119722.001]
  • [Cites] Adv Anat Pathol. 1999 Jul;6(4):186-203 [10410172.001]
  • [Cites] Am J Clin Pathol. 1985 Apr;83(4):426-30 [3984936.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):125-8 [3919599.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1303-13 [10541110.001]
  • (PMID = 19066954.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Liu HM, Wu FL, Chen X, Ye CS, Deng YJ: [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct;29(10):2115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the value of ultrasonographic grading with high-frequency probes in differentiating benign and malignant breast tumors.
  • METHODS: Sixty-four women (mean age 44.5-/+13.7 years) with 79 breast tumors underwent high-frequency ultrasonography to examine the tumor number, size, aspect ratio, shape, boundaries, encapsulation, pseudopod, internal and rear echoes, calcifications, blood perfusion, abnormality lymph nodes in the axilla.
  • RESULTS: Between the 46 women with benign tumors and 18 with malignant tumors, no significant differences were found in the mean tumor number (1.5-/+1.3 vs 1.1-/+0.3, P>0.05) or size (55.0-/+19.2 mm vs 19.8-/+8.3 mm, P>0.05), but the mean age (41.4-/+12.4 years vs 52.4-/+14.1 years) and ultrasonographic grade (2.8-/+2.2 vs 7.3-/+1.7, P<0.05) differed significantly.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Grading. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861280.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Wang JX, Yu JK, Wang L, Liu QL, Zhang J, Zheng S: Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics; 2006 Oct;6(19):5344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pattern 2 distinguishes papillary thyroid carcinoma from benign thyroid nodes.
  • [MeSH-major] Blood Proteins / metabolism. Neoplasm Proteins / blood. Peptide Mapping. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / blood. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / pathology. Carcinoma, Papillary / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Humans. Neoplasm Staging. Protein Array Analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16941571.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


84. Balogh GA, Mailo DA, Corte MM, Roncoroni P, Nardi H, Vincent E, Martinez D, Cafasso ME, Frizza A, Ponce G, Vincent E, Barutta E, Lizarraga P, Lizarraga G, Monti C, Paolillo E, Vincent R, Quatroquio R, Grimi C, Maturi H, Aimale M, Spinsanti C, Montero H, Santiago J, Shulman L, Rivadulla M, Machiavelli M, Salum G, Cuevas MA, Picolini J, Gentili A, Gentili R, Mordoh J: Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol; 2006 Apr;28(4):995-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serological p53 antibody analysis detected 0/8 (0%), 0/4 (0%) and 9/55 (16.36%) positive cases in normal women, in patients with benign breast disease and in breast carcinoma, respectively.
  • We found positive p53 mutant in the sera of 0/8 (0.0%) normal women, 0/4 (0%) with benign breast disease and 29/55 (52.72%) with breast carcinoma.
  • Immunohistochemistry evaluation was positive in 29/55 (52.73%) with mammary carcinoma and 0/4 (0%) with benign breast disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoantibodies / blood. Carcinoma in Situ / blood. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry / methods. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525651.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


85. Wu HH, Clouse J, Ren R: Fine-needle aspiration cytology of Hürthle cell carcinoma of the thyroid. Diagn Cytopathol; 2008 Mar;36(3):149-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective review of 35 FNA cases with the diagnosis of Hürthle cell lesion or Hürthle cell neoplasm was performed.
  • The FNA specimens were divided according to histologic diagnoses as HCC (12 cases), Hürthle cell adenoma (HCA) (14 cases), and benign nonneoplastic Hürthle cell lesions (BNHCL) (9 cases).
  • Each case was examined using a semiquantitative scoring system for the following 11 features: presence or absence of colloid, lymphocytes, and transgressed blood vessels (each scored 0 or 1); the percentage of nuclear enlargement, small cell dysplasia, large cell dysplasia, nuclear crowding, and cellular dyshesion (each scored 0-3); and age, gender, and size of lesion.
  • When diagnosed by FNA as either Hürthle cell neoplasm or Hürthle cell lesion, males were much more likely to have malignant tumors than females.
  • Statistically significant cytologic features that favored malignant (HCC) over benign lesions (HCA and BNHCL) included small cell dysplasia, large cell dysplasia, nuclear crowding, and cellular dyshesion.
  • The presence of colloid and lymphocytes favored a benign lesion.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18232004.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Callesen AK, Madsen JS, Iachina M, Vach W, Kruse TA, Jensen ON, Mogensen O: Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor. Cancer Biomark; 2010;6(2):73-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein profiles of 113 serum samples from women with an ovarian tumor (54 malign and 59 benign) were generated using MALDI-TOF MS.
  • A total of 98 peaks with a significant difference (p< 0.01) in intensity between women with benign tumors/cysts and malignant ovarian tumors were identified.
  • After average linkage clustering, a profile of 46 statistical significant mass peaks was identified to distinguish malignant tumors and benign tumors/cysts.
  • In the subgroup of women with normal CA125 values (< or =35 U/mL) (62 patients) 36 of the 504 mass peaks showed significant (p< 0.05) differences in intensity between benign and malignant disease.
  • The current study demonstrates the potential of mass spectrometry based serum protein profiling as a diagnostic tool in discrimination between benign ovarian tumors/cysts and malignant ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / diagnosis. Protein Array Analysis / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Peptides / blood. Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571233.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Peptides; 0 / Proteins
  •  go-up   go-down


87. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG: HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol; 2010 Apr;31(2):113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate (a) the expression of HE4 vs. OC mucin CA125 in 32 patients with OC compared to 163 patients with other malignant or benign pathologies (b) HE4 as indicator of the recurrence of the disease in eight patients followed-up for 20 months after OC diagnosis.
  • [MeSH-major] Biomarkers, Tumor / blood. Epididymal Secretory Proteins / analysis. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-125 Antigen / blood. Female. Humans. Middle Aged. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2002 Sep;3(9):529-36 [12217790.001]
  • [Cites] Mol Oncol. 2009 Apr;3(2):171-81 [19383379.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 1):2-7 [10071968.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Obstet Gynecol. 1988 Jul;72(1):23-7 [3164105.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):847-53 [16607372.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1395-403 [19195045.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Gynecol Oncol. 2008 Aug;110(2):196-201 [18495222.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):383-9 [15950183.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005, ix [12959188.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Rev Reprod. 1998 May;3(2):86-95 [9685187.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Can Fam Physician. 2008 Dec;54(12):1691-2 [19074707.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2768-73 [11965550.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91 [16174214.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1161-3 [11870155.001]
  • [Cites] Am J Epidemiol. 2008 May 1;167(9):1059-69 [18303003.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Biochem J. 2002 Nov 15;368(Pt 1):233-42 [12206714.001]
  • (PMID = 20358424.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


88. Mitterberger M, Pinggera G, Horninger W, Strasser H, Halpern E, Pallwein L, Gradl J, Bartsch G, Frauscher F: Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol; 2008 Jan;53(1):112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This study assessed the effect of premedication with dutasteride, a dual 5alpha-reductase inhibitor, on prostatic blood flow prior to prostate biopsy and its impact on prostate cancer detection.
  • RESULTS: Dutasteride reduced prostatic blood flow in benign prostatic tissue, whereas in prostate cancer areas blood flow was still observed after a 14-d course of dutasteride intake.
  • A reduction of blood flow was observed even after 7 d.
  • Twelve patients (33%) of our cohort were found to have suspicious blood flow and prostate cancer and six cancers (17%) were detected solely by targeted contrast-enhanced biopsy.
  • [MeSH-major] Azasteroids / administration & dosage. Biopsy / methods. Blood Flow Velocity / drug effects. Enzyme Inhibitors / administration & dosage. Prostate / pathology. Prostatic Neoplasms / diagnosis. Ultrasonography, Doppler, Color / methods
  • [MeSH-minor] 3-Oxo-5-alpha-Steroid 4-Dehydrogenase. Administration, Oral. Adult. Aged. Contrast Media. Dutasteride. Endosonography. Humans. Male. Middle Aged. Neoplasm Staging / methods. Reproducibility of Results


89. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ: A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1152-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used quantitative real-time PCR to measure relative telomere length in genomic DNA extracted from peripheral blood leukocytes and examined its association with postmenopausal breast cancer risk in 1,122 invasive breast cancer cases and 1,147 matched controls free of diagnosed cancer nested within the prospective Nurses' Health Study.
  • Other established breast cancer risk factors such as family history of breast cancer and history of benign breast disease were not associated with relative telomere length in separate linear regression models each adjusted for age and disease status (P > or = 0.07).
  • Our results provide little support for an important role of telomere length, as measured in peripheral blood leukocytes, as a biomarker of breast cancer risk.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 May 15;68(10):3618-23 [18483243.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1696-700 [18000505.001]
  • [Cites] Mech Ageing Dev. 2000 Nov 15;119(3):89-99 [11080530.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e47 [12000852.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 [12928346.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):984-8 [15300252.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2900-6 [3986816.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8 [1438199.001]
  • [Cites] Curr Opin Oncol. 1996 Jan;8(1):66-71 [8868103.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 [9731736.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1263-71 [15746160.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1823-30 [16567770.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:531-57 [16824017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 [17416776.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5538-44 [17545637.001]
  • [Cites] Aging Cell. 2007 Dec;6(6):769-74 [17925004.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5917-21 [10606235.001]
  • (PMID = 19293310.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082838; United States / NCI NIH HHS / CA / CA065725; United States / NCI NIH HHS / CA / R01 CA049449-19; United States / NCI NIH HHS / CA / R01 CA065725-05; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / T32 CA009001-33; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / CA132190-02; United States / NCI NIH HHS / CA / CA49449; United States / NCI NIH HHS / CA / CA009001-33; United States / NCI NIH HHS / CA / R01 CA065725; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R03 CA132190-02; United States / NCI NIH HHS / CA / T32 CA09001; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / CA132190; United States / NCI NIH HHS / CA / R03 CA132190; United States / NCI NIH HHS / CA / T32 CA009001; United States / NCI NIH HHS / CA / CA065725-05; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / U01 CA049449; United States / NCI NIH HHS / CA / R01 CA082838-09
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ NIHMS102391; NLM/ PMC2732000
  •  go-up   go-down


90. Saran R, Tiwari RK, Reddy PP, Ahuja YR: Risk assessment of oral cancer in patients with pre-cancerous states of the oral cavity using micronucleus test and challenge assay. Oral Oncol; 2008 Apr;44(4):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral cancer is preceded by some benign lesions or conditions, which are termed pre-cancerous.
  • In addition, challenge comet assay was carried out on peripheral blood leucocytes by using mutagen MNNG sensitivity of DNA after DNA repair.
  • A significant stepwise increase in the DNA damage (basal/MNNG-treated/post-repair) was observed in buccal epithelial cells and peripheral blood leucocytes from control to pre-cancer patients and from pre-cancer to cancer patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Aberrations. Comet Assay / methods. DNA Damage. DNA Repair. DNA, Neoplasm / genetics. Disease Progression. Female. Humans. Leukocytes / drug effects. Leukocytes / pathology. Male. Methylnitronitrosoguanidine / pharmacology. Micronucleus Tests / methods. Middle Aged. Mouth Mucosa / pathology. Risk Assessment / methods

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2008 Jul;44(7):716-7 [18381248.001]
  • (PMID = 17936677.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 12H3O2UGSF / Methylnitronitrosoguanidine
  •  go-up   go-down


91. Gaisa NT, Henkel C, Knüchel R: Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls. Curr Opin Urol; 2010 Sep;20(5):398-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours.
  • Whereas the identification of FGFR3 mutations has led to a better distinction of at least two pathways of urothelial carcinogenesis, additional multiparametric approaches may help improve the still inadequate search for urine and blood markers indicative of bladder cancer and/or its progression.
  • We are optimistic that an even more clear-cut distinction between benign recurring, nonprogressing tumours and more aggressive tumours will enable us to focus and limit chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Molecular Diagnostic Techniques. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625299.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


92. Marangoni K, Neves AF, Cardoso AM, Santos WK, Faria PC, Goulart LR: The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev; 2006;30(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
  • Pre-surgical peripheral blood samples from 160 patients were analyzed: 84 PCa, 11 prostate intraepithelial neoplasia (PIN) and 65 benign prostatic hyperplasia (BPH).
  • RESULTS: The GG and GT Glu-298-Asp genotypes were associated with positive DD3 expression in the peripheral blood, presenting a 3.32-fold higher risk of PCa occurrence.
  • [MeSH-major] Nitric Oxide Synthase Type III / genetics. Polymorphism, Genetic. Prostatic Hyperplasia / blood. Prostatic Intraepithelial Neoplasia / blood. Prostatic Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Gene Expression Regulation, Enzymologic / physiology. Genotype. Humans. Male. Nitric Oxide / metabolism. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length


93. Ludwig S, Stephan C, Lein M, Loening SA, Jung K: S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study. Prostate; 2007 Sep 1;67(12):1301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study.
  • BACKGROUND: To evaluate the diagnostic performance of plasma S100A8, S100A9, and the S100A8/A9 complex as novel markers to discriminate between benign and malignant prostatic diseases as recently suggested for S100A9.
  • [MeSH-major] Biomarkers, Tumor / blood. Calgranulin A / blood. Calgranulin B / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Aged. Enzyme-Linked Immunosorbent Assay. Humans. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. ROC Curve. Retrospective Studies. Risk Factors


94. Zustin J, Akpalo H, Gambarotti M, Priemel M, Rueger JM, Luebke AM, Reske D, Lange C, Pueschel K, Lohmann C, Rüther W, Amling M, Alberghini M: Phenotypic diversity in chondromyxoid fibroma reveals differentiation pattern of tumor mimicking fetal cartilage canals development: an immunohistochemical study. Am J Pathol; 2010 Sep;177(3):1072-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondromyxoid fibroma represents a rare benign cartilaginous tumor of young patients occurring in a subcortical metaphyseal location.
  • Vascularized cartilage canals growing into the fetal cartilage from the perichondrium displayed characteristic glomeruloid structures with central arterioles within the immature mesenchymal stroma and numerous superficial sinusoidal blood vessels accompanied by macrophage infiltration.
  • Based on the observed substantial morphological similarity between the cartilage canals and chondromyxoid fibroma, we suggest that the chondromyxoid fibroma represents a neoplasm originating from or mimicking the fetal cartilage canals within the immature cartilage.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):271-7 [11488075.001]
  • [Cites] J Bone Miner Res. 2010 Jun;25(6):1267-81 [20200945.001]
  • [Cites] J Pediatr Orthop. 2002 Mar-Apr;22(2):217-8 [11856934.001]
  • [Cites] Bone. 2004 Mar;34(3):454-65 [15003793.001]
  • [Cites] J Bone Joint Surg Br. 1971 May;53(2):198-216 [5578216.001]
  • [Cites] Anat Rec. 1972 May;173(1):79-93 [5028066.001]
  • [Cites] Hum Pathol. 1979 Jan;10(1):71-86 [428995.001]
  • [Cites] Acta Pathol Jpn. 1984 Nov;34(6):1285-300 [6524378.001]
  • [Cites] Acta Anat (Basel). 1985;124(1-2):54-7 [4072610.001]
  • [Cites] AJR Am J Roentgenol. 1986 Aug;147(2):317-21 [3524161.001]
  • [Cites] Tissue Cell. 1986;18(5):701-7 [3775757.001]
  • [Cites] Mod Pathol. 1990 Nov;3(6):664-6 [2263591.001]
  • [Cites] J Cell Biochem. 1996 Jul;62(1):1-9 [8836870.001]
  • [Cites] Hum Pathol. 1998 May;29(5):438-46 [9596266.001]
  • [Cites] Anat Rec. 1998 Sep;252(1):140-8 [9737750.001]
  • [Cites] Mod Pathol. 1999 May;12(5):514-7 [10349990.001]
  • [Cites] J Anat. 2005 Apr;206(4):359-72 [15817104.001]
  • [Cites] J Pathol. 2005 Jun;206(2):135-42 [15880456.001]
  • [Cites] J Pathol. 2006 Jan;208(1):26-34 [16278817.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1807-16 [17525249.001]
  • [Cites] Dev Dyn. 2007 Aug;236(8):2077-88 [17626280.001]
  • [Cites] Ann Anat. 2008;190(4):305-15 [18602255.001]
  • [Cites] APMIS. 2009 Jul;117(7):518-25 [19594492.001]
  • [Cites] Adv Anat Pathol. 2009 Sep;16(5):307-15 [19700940.001]
  • [Cites] Dev Biol. 2010 May 1;341(1):236-45 [20206617.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1009-20 [11549593.001]
  • (PMID = 20671262.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2928941
  •  go-up   go-down


95. Kruse AL, Zwahlen RA, Grätz KW: New classification of maxillary ameloblastic carcinoma based on an evidence-based literature review over the last 60 years. Head Neck Oncol; 2009;1:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current classifications do not consider benign histopathological features at the primary and malignant features at the metastatic tumour site.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Evidence-Based Medicine. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Ameloblastic carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 1993 Oct;51(10):1152-5; discussion 1156-7 [8410456.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1993 Jul;29B(3):169-71 [8298419.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Mar;31B(2):86-99 [7633291.001]
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):1019-22 [7499939.001]
  • [Cites] Diagn Cytopathol. 1996 May;14(3):249-52 [8732656.001]
  • [Cites] J Oral Pathol Med. 1998 Jan;27(1):39-42 [9466734.001]
  • [Cites] J Craniomaxillofac Surg. 1998 Jun;26(3):159-62 [9702634.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Apr;65(4):777-83 [17368379.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):799-807 [17448710.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Sep;65(9):1800-3 [17719401.001]
  • [Cites] Ann Surg. 1948 Nov;128(5):999-1005 [17859260.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Dec;104(6):e17-24 [17942338.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):175-6 [16652346.001]
  • [Cites] Pathologe. 2008 May;29(3):214-20 [18330573.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):649-53 [11402276.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Jan;60(1):102-4 [11757019.001]
  • [Cites] J Craniomaxillofac Surg. 2002 Oct;30(5):273-9 [12377199.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Jun;61(6):731-4 [12796889.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):736-41 [12907214.001]
  • [Cites] J Can Dent Assoc. 2003 Oct;69(9):573-6 [14653932.001]
  • [Cites] J Craniofac Surg. 2004 Mar;15(2):264-9 [15167247.001]
  • [Cites] Laryngoscope. 2004 Oct;114(10):1770-4 [15454770.001]
  • [Cites] Bull Tokyo Dent Coll. 1972 May;13(2):91-101 [4504978.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Feb 9;381(2):211-22 [154765.001]
  • [Cites] J Oral Surg. 1980 Mar;38(3):203-6 [6928185.001]
  • [Cites] Am J Clin Pathol. 1981 Apr;75(4):585-91 [7223720.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Sep;54(3):299-303 [6957827.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1983 Sep-Oct;92(5 Pt 1):532 [6625456.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1984 Feb;57(2):168-76 [6366686.001]
  • [Cites] J Oral Med. 1986 Apr-Jun;41(2):79-81 [3459830.001]
  • [Cites] J Maxillofac Surg. 1986 Dec;14(6):338-40 [3467002.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Nov;64(5):570-6 [3313152.001]
  • [Cites] Am J Clin Pathol. 1988 Oct;90(4):474-81 [3052019.001]
  • [Cites] J Otolaryngol. 1989 Apr;18(3):109-11 [2716084.001]
  • [Cites] J Craniomaxillofac Surg. 1990 Aug;18(6):247-50 [2212021.001]
  • (PMID = 19674470.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2733136
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


96. Kaliszewski K, Łukieńczuk T, Dobosz T, Rzeszutko M, Sadakierska-Chudy A: [Analysis of expression of LGALS3BP gene in thyroid tissues and peripheral blood lymphocytes in patients with papillary thyroid cancer]. Endokrynol Pol; 2006;57 Suppl A:38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of expression of LGALS3BP gene in thyroid tissues and peripheral blood lymphocytes in patients with papillary thyroid cancer].
  • AIM: Analysis of Gal-3 protein expression in PTC and nodular goiters; investigation of Gal-3 mRNA expression in peripheral blood lymphocytes (PBL) in patients with PTC and nodular goiter; analysis of correlation between Gal-3 protein expression in PTC and Gal-3 mRNA in PBL of the same patient.
  • MATERIAL AND METHODS: Gal-3 protein was evaluated by immunohistochemistry in benign (27 multinodular goiters) and malignant (30 papillary carcinomas) thyroid tissues and galectin-3 mRNA expression by real-time PCR in peripheral blood lymphocytes (PBL) from 90 patients with multinodular goiter (n = 27), papillary carcinoma (n = 30) and healthy controls (n = 33).
  • 23 of 27 benign thyroid nodular goiters were negative for Gal-3 expression.
  • In all examined blood samples we observed higher LGALS3BP gene expression than GAPDH (house keeping gene) with no difference between both groups, without relation to the Gal-3 expression in PTC.
  • CONCLUSIONS: There is no difference in Gal-3 expression in peripheral blood lymphocytes in patients with papillary thyroid cancer in relation to nodular goiter.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carrier Proteins / genetics. Gene Expression Regulation, Neoplastic. Glycoproteins / genetics. Lymphocytes / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091455.001).
  • [ISSN] 2299-8306
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / LGALS3BP protein, human; Thyroid cancer, papillary
  •  go-up   go-down


97. Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP: A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics; 2006;7:539
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For validation purposes we choose the intracranial meningioma tumors as model system since they occur very frequently, are mostly benign, and are genetically stable.
  • RESULTS: A total of 183 blood samples from 93 meningioma patients (WHO stages I-III) and 90 healthy controls were screened for seroreactivity with a set of 57 meningioma-associated antigens.
  • [MeSH-major] Algorithms. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / immunology. Meningioma / diagnosis. Meningioma / immunology

  • Genetic Alliance. consumer health - Meningioma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6 [12601173.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3034-44 [15226172.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] J Urol. 2005 May;173(5):1456-62 [15821460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9601-6 [15983380.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1792-8 [16452240.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):736-8 [16915260.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 17184519.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1769403
  •  go-up   go-down


98. Lee JH, Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest; 2005 Oct;128(4):2298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using cutoff values of 5 ng/mL, 20 ng/mL, and 3.3 ng/mL for serum CEA, NSE, and CYFRA 21-1, respectively, the sensitivities and specificities of these tumor markers were as follows for differentiating malignant effusion from benign: CEA, 68% and 93%; NSE, 34% and 93%; and CYFRA 21-1, 45% and 100%.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Keratins / blood. Lung Neoplasms / diagnosis. Phosphopyruvate Hydratase / analysis
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Case-Control Studies. Humans. Keratin-19. Peptide Fragments / analysis. Pleural Effusion. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236887.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptide Fragments; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


99. Alonzi R, Padhani AR, Allen C: Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol; 2007 Sep;63(3):335-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiogenesis is an integral part of benign prostatic hyperplasia (BPH), is associated with prostatic intraepithelial neoplasia (PIN) and is key to the growth and for metastasis of prostate cancer.
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Prostate-Specific Antigen / blood. Prostatectomy. Radiotherapy Planning, Computer-Assisted

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689907.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 51
  •  go-up   go-down


100. Mentzel T, Schärer L, Kazakov DV, Michal M: Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol; 2007 Oct;29(5):443-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatofibrosarcoma protuberans (DFSP) represents a locally aggressive mesenchymal neoplasm of skin and subcutis with characteristic clinicopathologic, immunohistochemical, and molecular findings.
  • Numerous blood vessels with slightly fibrosed vessel walls were seen in seven cases.
  • In conclusion, myxoid DFSP represents a very rare morphologic variant with characteristic changes that has to be distinguished from benign and malignant myxoid mesenchymal neoplasms as superficial angiomyxoma, superficial acral fibromyxoma, myxoid solitary fibrous tumor, myxoid perineurioma, low-grade myxofibrosarcoma, low-grade fibromyxoid sarcoma, myxoid liposarcoma, and myxoid synovial sarcoma.

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890911.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Collagen Type I; 0 / Mucin-1; 0 / Proto-Oncogene Proteins c-sis; 0 / collagen type I, alpha 1 chain
  •  go-up   go-down






Advertisement